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Abstr:1ct
Midazolam (Hypnovelll:) is the only sedating agent used by paramedics at St John
Ambulance Service W.A. in the management of many conditions including seizure
activities, antisocial or uncontrollable behaviours. back pain incidents and head injuries.
Midazolam, with a rapid absorption, fast onset of action and short duration on
neurological activity, has been accepted as a safe and effective agent in prehospital
treatment since the late-1990s. Often. if a patient is not complying with treatment or is
uncontrollable or aggressive, paramedics are required to sedate the individual. This
study primarily examines the use of midazolam for the sedation of unmanageable
patients who have sustained a head injury in a prehospital setting. The research
investigated \vhethcr miduzolam (n=49) increases the symptoms of hypntcnsion and
hypoxia in patients with head injuries in a prebospital setting. Patients that

sust~ined

a

head injury but did not receive midazolam (n=47) were used as controls. Physiological
parameters including blood pressure, pulse and respiration rates, oxygen saturation,
along with Coma Scale and Visual Analogue Scale were placed into SPSS analysis
packuge and Excel t-h.'Sts. further unalysis on sub divided cohorts of gender, age and
severity of head injury was conducted. Results indicated that although significance
differences were present, miduzolam did not inlluence hypotension or hypoxia in

h~Jad

injured patients. However the nature of the head injury along with behavioural issues
was the result of incrcused symptoms of hypotension and hypoxia.

l. Introduction
Midazolam (llypnovci'!i:) is the only sedating agent used by paramedics at St John
Ambulance Service W.A. in the

managem~nt

of many conditions including seizure

activities, antisocial or uncontrollable behaviours, back pain incidents and head
injuries 1. Midazolam is a member of the bi:nzodiazepine family of drugs and is regarded
as a safe alternative to opiates and barbiturates

1
.

Its lipophilic properties enable rapid

absorption into the brain with fast onset or action. Similar to diazcpmn hut with a
shorter duration on neurological activity, midazolam has been accepted as a safe and
effective agent in prehospital treatments since the late-1990s.

Emergency medicine rcqmrcs paramedics to expertly manage critical care patients,
sedated patients, pain managed patients, as well as respiratory and haemodynamieally
compromised patients. When paramedics arrive at the scene of a severely injured or
hacmodynamically compromised individual the policy is to cnsun: the patient is
ddivercd to hospital in a safe and stable manner. For trauma patients the policy that
ensures effective transport to hospital, where appropriate treatment can begin, is to
maintain minimal time ut the scene of an accident and maximum treatment on route 1.

Often if a patient is not complying with treatment or is uncontrollable or aggressive,
paramedics arc requin;·d to sedate the individuaL In the prehospital setting the bst resort
is to administer a sedating agent to a patient who is cerebrally hypoxic. has sustuined a
head injury or is agitated. llmvcver, it is considcrcd appropriate to sedate to manage.
regardless of a patients· physiological status.

In other words, midazolam can be

administered to a patient \vho is not compliant or is uncontrollah\c, in order for them to
be transported to hospital for appropri<.ttc treatment

J.

There is a growing amount of literature suggesting that midazolam is a safC and
effective sedating agent when used in a prchospital setting for seizures and agitated or

II owcver. some recent pu hi'!Catwns
.
.md'1cate poss1'bl e negat1vc
.
side effects associated \Vith midazolam and head injured patients. As Davis (200 I) 11
. patH:nts
.
psyc I10t1c

~·HI .

suggests increased doses of midazolam can be associated with a detrimental outcome to
patients

\V\lll

have sustained head injuries.

2

This study will primarily examine whether midazolam influences hypoxia and/or
hypotension d11ring sedation of unmanageable patients in a prehospital setting who have
sustained a head injury. The majority of patients in this study had sustained a closed
mild or moderate traumatic brain injury, with a small number of cases having sustained
a severe traumatic brain injury (TBI).

3

1.2.Aims
To evalUate the effect of midazo!am in patients with a head injury in the prchospital
setting.

Ultimatc\y the research will investigate whether midazolam increases the symptoms of
hypotension and hypoxia in patients with head injuries in a prehospital setting ..
Patients that sustained a head injury but did not receive midazolam will be used as
controls.

4

J

2. Literature Review

2.1. Mic.lazolam
The synthesis of midazolam was discovered by Fryer and Walser in 1976

11

.

Today

midazolmn is kno\\ll by the brand names Versed R.. llypnovcl ~ atH.I Dormicum R.
Midazolam is <t Schcduh: 4 drug (requiring pn:scription) undo::r the Poisons Act \%4
(\VA). l!ypnovel" is the brand of mid<.~zolam ttscd by paramedics at StJohn Ambulance
Service W.A. Midazolam is a short acting benzodinzcpinc that induces scdution.

hypnosis. amnesia and anaesthesia \Vith the c!Tccts on the CNS depending on the dose
received, the route of administration and the pn:scncc or absence of other m..:dicatinns.

Aller intrav!.!nous administration at a dose of 5 to lOmg. onsd of S!.!dution will occur
within 2 to 3 minutes, followed by peak sedation for the individual at 30-60 minutes
following injection u. Miduzolam has been known to cuusl! an anaesthetic state among
individuals. llowever, 14%
miduzolam alone

ofp~1ticnts

will not reach anaesthetic

stat~

with the i.ISL' nf

l.t.

2.1.1. II istory of the implementation of midazolam in pre hospital care in Austrulin.

Midazolum (llypnovcl~. Roche) has many clinical uses and has bcl!n used not only t()r
its sedative actions. hut for the managl!ment or seizure activity. back pain and antisocial
or aggressive behaviours in prchospital settings. From the beginning of April 1997
NSW paramedics bcgan using midazolum in thc prchospital setting as it was found to
produce equal clinical effects to those of diazepam. a commnnly used scdati\'e, ''ith
fl!wcr complications of respiratory dcprL·ssion in

pati~.:nt.». Morcov~.:r.

miJaznlam has a

hulflife of 2-3 hours wmpared to a half life of(, lwurs fer diazepam making miJaznlam
a more appropriate drug to use in prehospit<ll cnrc

7

•

Thus miJazolam provides patients

with !~1st actin~; treatment without prolonged sedution u.

Midazolum was first introduced as a sedating agent at StJohn Amhulanec Service \V.A.
!Or the manag.ement of fits or scizmc activity in \999. In 2003 midazolam wus
implcmcnicd as a sl'dating agent ti.x antisoeial or aggre.s.si\"L' hchaYiours in the
prchospital setting. By 2004 midazolam wa:-. also introdueed as a pain management toni
for back pain symptoms

15 17
. •

Prior to that midazolam's primary usc

\\liS

as a sedative

agent during minor surgical procedures in hospital care. Midazol<.un is now widely

5

The structure of midazolam is 8-chloro-6-(2·1luorophcnyl)-l-mcthyl·41-l-imidazo!l.5·
a][I.4J bcnzodiazcpinc (Figure 2.) and the chemical formula is ClRih:,CIFNJ. The
compound has a molecular weight of 325.8 and in its non active state it is a solid white
or yellowish crystal"''l .

Cl

0

'-,-==-r.
F

0

Mldamlam

f"igw·~ 2. A s/ntc/1/rul il/uslrulion oj111ida::o!um

!l.

Midazolam manufactured for injection is a clear c.olourless or faint yellow solution that
contains midazolam as a salt together \Vith sodium chloride in sterile water. At a pl-1
between 2.9 and 3.7 each prepared injection is available in lmg/ml and Smg/ml
strengths.

2,1.3. llosagc and Administration orMidazolam

The dosage of midazolam administered to patients varies depending on the patient's
symptoms (Table I). The preferred route of administration of midazolam in the
prehospitul setting is intramuscular. Intramusculur administration has been shown to be
an easier and safer form of administration for lilting or aggressive patients

7
•

Alter

intramuscular administrution the onset of midazolam effects will occur \Vilhin I to 5
minutes. The time of onset will vury for each individual and will depend on the rate of
absorption from muscle. The onset of midazolam etlCcts is also strongly dependent on
an individual's genetic makeup, particularity to the genes coding for drug metabolising
ability 23 •27 •

7

Table I. Dosage or midazolam used lOr patients in prcbospital setting 28
Atlult l>ost· of Mida:.wl11m mg
Seizures

I Omg
il' h·ai! ur over 6S - ha! f adult dose

----~

Antisocial

-----c~

Baek Pain

-----Mid~tzolam

10-25mg
--

2.5-Smg

--

is absorbed hy as much as 80 to

I 00% following intramuscular

administration and ;tccmding Ill DunJec e/ al (1984)P produces greater sedation, more
amnesia. a signilicant anti<mxicty cfll:ct anJ less pain at the injection site compared to
hydruxyzinc or dia1.1...'pam.

It is important to mention thut cmcrgl!ncy situations arc

has~...·d

on rapid

asscs~mcnt

and

administration or treatment. hence weight is not considered by thL' W.A. Ambulance
Scrvicl.! Clinical Practice Guiddines ts~...·~...· uppenJix 1) and doses administered to patients
arc not b<.1sed on the patient's weight.

2.1A.I)rinu•~·

Indications of Mido,zolam in the Prchosptial Setting

The t\VO primary indications of thl! use of midazolam in W.A. pre hospital Sl.!tting Ufl! for
seizure activity and anti-social or unnwrmgeabk bdmviour. There is a growing ameunt
of litcraturl! that suggests that midazolam is an accl!ptablc si!Uating agent used in
. I care to treat acutl! se1zure
. . 111
. paucnt-.;
.
"
pre I10sp1ta
ncttvtty
· ··'· ,,. 1.11c stu dy con ducte db y

RainbO\V ct a/ (2002) 7 suggested that midazo\an1 is morl! cflL-L"tivc than diazepam in
controlling seizures in childrl.!n in a prdmspitul setting. '\11c study demonstrated that
there were significantly ll:wer cusl!s of respiratory di.!pression whl:n midazo\am was
used compared to diazl!pam. /\\so the mean dosage of midazolam administered to
patients was significantly less than that or diazepam

7

•

A separate study conducted by McGlone and Smith (200\ ) 5 indicated that intranasal
midazolam (0.2mg) is more c!Tcctivc and less invasive than intravenous diazepmn for
treatment of seizure in children in emergency care. 1\arbord el a/ (2004)9 also found that
(0.2-0.3mg) intranasalmidazolam is more effective and easier to administer than rectal

8

diazepam for children with acute seizures in the community setting. Moreover, the
overall time fOr cessation of

scizu~~3

in children is quicker with the u.se of intranasal

midazo\am (0.2mg/kg) than with intravenous diazepam (0.3mg/kg)
(2005)

10

4

.

Shah et a!

also suggests that intramuscular midazolam (0.2mg/kg) is safer and more

effective than intravenous diazepam (0.2mg/kg) in the control of seizures irrespective of
the type of convulsion and age of the child. Ultimately these studies found that
midazolam is safe and easy to administer and the time to treat seizures is reduced
compared to diazepam.

The second most common use of midazolam is for the treatment of aggressive or
unmanageable behaviours in patients that may be due to severe illness such as mental
illness, substance misuse or head injuries. If the patient cannot be calmed by words,
sedation of the patient may be unavoidable. There arc studies that suggest midazolam is
a safe and cf!Cctive sedating agent for the control of anti-social or aggressive patients in
prehospita\ carer;. The TREC (Text REtrieval Conference) Collaborative Uroup8 found
that administering 7.5mg to 15mg of midazolam consistently sedated aggressive or
agitated patients for up to t\vo hours. Although haloperidol and promethazim: were also
used in this study intramuscular administration of midazobm \Vas clearly more effective
with minimal adverse effects x. Huf et (I{ (2002/ agrees that there arc few adverse
effects associated with the usc of intramuscular administration of midazolam in agitated
or violent patients. The dosage

or midazolam used in the study

by Huf et (1/ (2002/'

varied from 3-1 Omg depending on the clinical condition of the patient and previous
exposur-:: to other drugs.

9

2.1.5. Contraindicutions and

~ide

cfrccts of Midazolum

While there arc many studies that support the safety and efficacy of midazolam when
used as a sedating agent, there arc several side effects which include rcspimtory
depression as the most concerning

29 31
- .

Early studies conducted by Dundee e/ a/

(1984) 13 suggest that intravenous midazolam causes a decrease in tidal volume that is
compensated for by an increase in respiratory rate. A benzodiazepine antagoni:;t
flumazenil can reverse the respiratory complications and sedation induced by
midazolam

6 8 32
• • •

Other side effects or minor adverse reactions in patients after intramuscular
administration of midazolam include: headaches (1.3%) and/or local effects at the
injection site (pain (3.7%), indurations (0.5%). rcJncss (0.5%) and muscle stiffness
(0.3%)

33

•

On rare occasions midazolam provokes hostility and violence instead of

calming effects in patients

32

.

Other adverse reactions reported with intramuscular

administration of midazolam arc given in Table 2.

10

Table 2. Adverse Reactions of Intramuscular Administration of Midazolam

33

Complication

Type of Reaction

Respiratory

Laryngospasm, bmnchospasm, dyspnoea,
hyperventilation. wheezing, shallow
respirations,
mrway
obstruction,
tachv moea.
Bigeminy.
premature
ventricular
contractions, tachycardia. nodal rhythm,
vasovngal
cardiovascular
collapse,
cnisodc. cardiac arrest.
Acid taste. excessive salivntion, r~.:tching.

Cardiovascular

Gastrointcstitml
C NSIN curomuse ul ur

Ophthalmic

Dermatolt1gic

hcadm.:he,
Anterograde
amncsm.
euphoria. confusion. argumcntati vencs~.
llCfVOlLSlles:.;,
agitation,
anxiety.
grogginess,
restlessness,
irrit<~bility.
delirium
or
agitation.
emergence
prolonged emergence from anaesthesia,
dreaming during emergence. sleep
nightmares,
disturbance.
tnsomnta.
tonic/clonic lllOVCllll.!lltS, muscle trcmor.
involuntary
lllOVI!JllelltS.
athetoid
Jl10\'Cl11Cilts, dinincss, ataxia. dysphoria,
slt.!_rrcd spcccb.:~~~lH)nia. paril.L'sthcsia.
BlurrL·d \ lSIOtl. Jiplopia. nystagmus.
pinpllint pupils. 1'ydic 111\l\'elll!.!tltS
+-;~\'elids. di rticl! l.!)~it.U~ JC~~"ing
I li\'cs. hi\'c-likc ele\'ation at injection
burning.
site. S\\'CJling or rc~.:ling
W(lnll\h or cniJncss at injection site.
L"f~ them a. rash. Jlruri tus.
l:'<.mning. lethargy. chills. weakness.
continucJ phonation. cars blockct.l. loss
balanc(!. \ight-hl.'adedncss. toothache,
l·aint fccl~mcmatllllla.

or

or

-~~----

Miscellaneous

or

II

---

2.1.6. Pharmacology and Mechanisms of Action of Miduzolam

The structure of midazulam provides it with lipophilic properties allowing the drug to
cross lipid membranes. particularly the blood-brain barrier and affect the Central
Nervous System (CNS)

2

•

Midazo!am is also known to act on peripheral nervous tissue,

resulting in coronary vasodilation and neuromuscular blockages at very high doses

19

•

Midazolam like bcnzodiazepines has an affect on the CNS. There is a scarcity of
literature available on the specific regions of the CNS that arc affected by midazolam.
However the mechanism of action of midazolam in general on the CNS is via binding to
the gamma-wninobutyric acid (GAllA) receptor. GAllA is a naturally occurring
neurotransmitter round in the CNS

2 34
·
•

The GJ\BA receptors, membrane bound

proteins, arc divided into two major subtypes: GABAA and GABAn receptors

19

•

GABAA receptors induce sedation and anti-anxiety effects and arc located in the
cerebellum and spinal cord of the CNS

35

.

GABAB receptors are located in the basal

ganglia and hippocmnptls. These receptors are associated with muscle relaxation as well
as memory and learning.

Midazolam binds to the GABAA receptor. resulting in physiological effects such as
sedation, decreased anxiety, amnesia, muscle relaxation, anaesthesia and anticonvulsant
activity

2

•

This area of interest requires more research and is continually being

investigated.

2.1.7. The GAHAA receptor complex

The GABAA receptor complex belongs to a large family of hetcro·oligomeric ligandgated ion channels. The ionotropic GABAA receptor is composed of five known
subunits that contain recognition sites for various chemical agents. The GABAA
receptor complex contains recognition sites f(n; GABA ngonists and ant::lgonists, u
barbiturate binding site. a bcnzodiazepinc binding site. a steroid binding .site and a
picrotoxin binding site {Figure 3)

12

•

Uhimatc\y the binding of midazolam to its

recognition site results in an increased influx of chlorine ions, which result
hyperpolarisation m the post-synaptic membrane and inhibition or ncurotransmission

11

111
Jh.

Figure 3. An illustration ofthe GABA14 receptor complex, showing recognition sites for GABA,
barbiturate, benzodiazepine, steroid and picrotoxinin 11.

Benzodiazepines are known to modulate the binding of GABA to the GABAA receptor
ultimately altering binding in an allosteric fashion

12

•

Benzodiazepines can act as

agonists (positive modulators), inverse agonists (negative modulators) or as antagonists
(blocking both positive and negative modulators), depend ing on the benzodiazepine
compound and the subunit composition of various GABAA receptor isofom1s

37 38
•
.

Benzodiazepine agonists binding to the GABAA receptor site will increase chlorine ion
influx and inverse agonists will decrease chlorine ion flow. Midazolam acts as a

.

positive agonist displaying inhibitory functions when binding at the GABAA receptor
site

23

.
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Figure 4. A schematic diagram ofhyperpolarisation activity
during inhibition ofGABA J8_

When midazolam binds to the GABAA receptor there is an influx of chlorine ions
resulting in hyperpolarisation activity of the cell membrane (Figure 4) 38 . Ultimately the
influx of chorine ions suppresses neuron activity at specific neurons in the CNS
resulting in sedation or relaxation of the individual.
13

2.1.8. Metabolism of Midazol:tm via cytochrome P450 Drug Mctaholising Enzymes

Midazolam is predominately metabolised by the hepatic cytochroml! P450 drug
metabolising system. Mammalian cytochrome P450 proteins (CYP450) arc a group of
haenHhiolate monooxygenases that play a major role in drug metabolism. Cytochrome
P450 enzymes <tel via an

NADPI-l~dcpendent

electron transport pathway and have the

ability to form multiple interactions with a variety of xenobiotie compounds

39

•

The

name 'cytochrome P450' is derived from the absorbance spectrum of the haem
containing protein, characterised by a maximum absorption wavelength of 450nm when
reduced in the presence of carbon monoxide (CO)

40

•

The P in CYP450 stands for

pigment hence the abbreviation, P450 40• 41 •

Midazolam is one such drug that is metabolised by cytochrome P450. Many studies
suggest that CYP450 enzymes contribute to 70 -90% of the metabolism of midazolam
in individuals

26 27
· .

P450 proteins are categorised into families, subfamilies and single

cytochrome P450 enzymes. There arc 18 families
(CYPX\~2) of cytochrome P450 found in lwmans

(CYP1~18)
40

•

and 43 subfamilies

Thc predominant form of

cytochrome P450 is CYPJA, clustered on chromosome 7. Many of these protcins are

.
.
. I ep1t
. I1e 1·mm an d tI1e '·,.;1"d ncy ''~. " . Tl1C maJm
. roc
I o 1·
expresscd .Ill 1·1ver tissue,
mtestma
CYP450 enzymcs is to catalyse the phase I reaction of drug metabolism which involves
oxidation, reduction or hydroxylation reactions, to modify the xcnobiotic, making it
more easily excreted. /11 dm studies show that fl1ur members of the CYPJA subfamily
contribute to midazolam clearance in the body; CYPJA4, CYP3AS, CYP3A 7 and
CYP3A43 2u

1
•

Being a water soluble compound midazolam is carried via transport proteins in the
blood to the liver where it is metabolised to less activc metabolites. During the first
phase of mctabolism midazolam is hydroxy Ia ted by CYP450 into three metabolites; 1hydroxymidazolam (1-0IIM) (responsible

fOr 63% of midazolam activity). 4-

hydroxymidazolam {inactive) and 1~hydroxymidnzolam glucuronide ( 1-0llMG) (6% of
midazolam activity) .w.

45

4.1- •

The production of !~OHM is the predominant pathway of

14

midazolam metabolism accounting lOr 95% of the process, with only 5% metabolised to
4·hydroxymidazolmn 45 ,

Genetic variations m human population groups exhibit various polymorphisms.
Polymorphisms with CYP450 genes that code for the multiple enzymes are thought
responsible for a large proportion of genetic variation in drug metabolism ability and
sensitivity to drugs. A variation in drug metabolising ability determines \'ihcther
individuals arc good or poor mctabolisers of alcohol or other drug agents
research is not completely understood and requires further investigation.

15

46

•

This area or

2.2. What arc the causes of Head Injuries in W.A '!
Midazolam is commonly used by paramedics to treat unmanageable p.1ticnts who have
sustained a mild or moderate hc<1d injury. The di rtCrcnt head injuries assessed within
this study inciUlh;o: l'rm:tun:s, lacerations, <!brao;;ions, swelling, bleeding, tenderness or
contusions.

Road trauma accidents are a growing concern for community and health departments in
the state of W.A. There was a 26.4% increase in the number of head injury admissions
to Royal Perth Hospital (RPH) from 2003 to 2004. The 2004 RPH Trauma Registry
Report sl<tlcs tlmt 48% of adm;ssions of major traumas urc a result or road accidents. Of
this group. 25% ol' cases sustained head injuries in a motor vehicle at:cident. Other
major causes of head injuries in W.A. were; 38% as a result of a lUlL 21% struck by an
object, 6% were involved in motor bike accidents. 3% as pedestrians, 3% as pedal
cyclists, 1% were sporting or

rccre<~tional

accidents, 1% were gunshot or stabbing

accidents and I% were horse riding accidents 47 •

In 2004 85% of major trauma admissions to RPJ-1 were via ambulance transporl<!tion,
escorted by a StJohn Ambulance paramedic. Management of pntients with head injuries
is important to ensure minimisation of secondary brain injury. t-,.ianagement and
prevention of secondary brain injmy must begin at the scene of the accident. To ensure
suflicicnt management and prevt:ntion of secondary brain injury early detection of
injury. rapid tmnsportation to hospital and resuscitation lo prevent deterioration in the

. arc reqwre
. d hy t hc pamme d'1cs ~R ~'I.
palicnt

The Brain Injury Association of W .A. Inc states: "Bruin Injury is not a disease. or

something you mn •· catch". Brain Injury is de.fined

liS

a los_.,.

t~l hl'llin jimction,

hy accidents. poisoning. stroke, hrain 11/IIWUrs. infi:i.'l ions or lack t!/' oxygen

(Tnblc 3).

16

50

"

aw..,·ed

Table 3. Causes of !lead Injuries

50

Cause

Description

Accidents

Brain tumours

Road accidents, Sport and/or work
related. assaults. shaking your child.
Drinking to much alcohol. overuse
prescribed drugs. usc
illegal drubs,
petrolund chemical snining.
Rupture of a blood vessel Ill the brain,
block~c of hlood supply to the brain
CanccrOllS or non·canccrous

Infections

Meningitis. Enccphnlitis

Lack of oxygen

Ncar drowning. severe asthma attack,
lack of blood flow to the brain (heart
attack).

Poisoning

Stroke

or

17

or

2.2.1. How is the brain injured?

Traumatic brain injury (TBI) is a major problem with both high mortality and high
morbidity. Almost 2% of Australians have acquired head injuries with resulting
disabilities

5

(1.

Injury to the brain may occur at the time of injury (primary injury) and/or

subsequently dL1C to cerebral ischaemia (secondary injury). llypotension and hypoxemia
arc causes of secondary brain injury. Many studies have confirmed that outcomes
following traumatic hrain injuries result in individuals experiencing cognitive and
behavioural symptoms dt1ys. weeks even months after the trauma. Ranging symptoms
may include headaches. vertigo, sensitivity to bright lights and/or noise. blurn:d vision.
insomnia. restlessness. reduced concentration and memory probh:ms, irritability.
IUtiguc. an.xiety and depression

51 57
• •

When brain injury has occurred it is crucial lOr

prehospital management to focus on preventing secondary brain injury and minimising
t1c
I cIlances o f a poor outcome

.t'J 'iH '\9

·· ·· .

Paramedics at StJohn Ambulance encounter many incidents of head injured patients.
The majority of patients in this study have sustained a mild or moderate 1'[31. Mild or
moderate TB!may involve the head being injured as a result of a fractures, lacerations.
abrasions, swelling. bleeding, tenderness or contusions.

18

2.2.2. Glasgow Coma Sc:llc (GCS)

The Glasgow coma scale (GCS) is the most widely used scoring

syst~m

in

ass~ssm~nt

of the level of consciousness for patients \Vith head injuries in a prchospitul situation.
'I he Glasgow coma scale score provides a simple measure of patients' level of
consctousncss with u high degree of reliability. h is simple and easy Ill use: its
observations arc based on eye response. verbal response anJ motor response (Table 4 ).
The

Gl<~sgO\v

coma scale score provides paramedics with an asscssml.'nt tool for

patients' conscious state which enables satisfactory nwnagcmcnt of the p. :...:nts' injuries
prior to hospital admission.

Table 4. Glasgow Coma Score table 3
Eye Opening (E)

Verbal Response (V)

Motor Response (Ml

4 -- Spontaneous

5

Norrnal Convcr:->atinn

6

3- To voice

4

DisoricntaJcd con\-crsation

5- Localised tu p<til\-

2- To pain

3- Words. hut not coherent

~-

1- None

::! -No \\ords. only suunds

3 = Dcconicah:

1- None

::! - Decerebrate

=

Normal

\\'ithdr<ms to pain
pu~\ure

I -Nunc
Total
-··

19

E+V+l\1

2.2.3. Mild Tmumat11L' Brain Injury

A mild tnmmatic bruin injury can be defined by any of the following: ( 1) Direct contact
to the hend, due to outside forces or to accc\eration/decclcration trawn:.. (Ca1is). (2} Loss
of consciousness (LOC) expcricnct:d by the individual is usually brief, lasting seconds
to minutes, and in some cases no Joss of consciousness is c.xp!..'rienccd; only a dazed
consciousness occ 1rs. (3) The paticnt"s evaluated UCS is 13 to 15. Only a GCS score of
IS represents a trul mild TBL (4) Confusion along v..-ith amnesia is experienced by the
patient

Justin~~

minutes to a few hours. \vhether or not there arc periods of

unconsciousness. (5) No !i.1ca\ signs an: pr·:scnt in the patient; the patient may also have
. b e d'mp I1oret1c
. amI expenence
.
. ~>o hi .
a paIe comp Iex1on,
nausea or bc at:tXIC

2.2.4. Moderate Traumatic Brain Injury

A Moderate Tmumatic Brain Injury (TBl) has a GCS grading of9 to 13. Moderate TBI,
like mild TBJ. can result in the head being i11jurcd from fractures, lacerations, abrasions.
amnesia or contusions. individuals with n modemte TBI pose a greater risk of
developing secondary brain injury. Fifty percent ol'mndcrate Tl3J patients suffer longterm disabiiitics 62 •
2.2.5. Severe Traumatic Bruin Injury

A severe TBI has a GCS score orless than 9. The causes of severe TBI arc identical to
those of mild TBL \.Vith the exceptions ofwhiplasl'

~md

assaults that occur more

commonly \'.ith mild TBl ~>o. Severe TBI occurs 1l:om considerable forces exceeding the
skulls tokranc.c; the greater the force the greater the injury. This may include a fracture,
laceration. abrasion, amnesia or contusion,

htm~ver

to a greater degree of severity.

Other indicators of severe Till may be continual brain stem rc!1cx posturing, increased
intracranial pressure (ICP). hypertension and incrc<:~scd body tcmpcmture

20

63

•

2.2.5.1. Skull Fractures/Direct !lead lltiury

Skull fractures arc often catt.!goriscd as basilar, linear, depressed or comminuted skull
fractures that arc either open or dosed. Skull fractures arc often the result of a force that
penetrates or fractures the skulL causing thl.! skull to bend imvards at the site of impact

. curve out\vurd s aroun d tI1c s1tc
. o f.1m pact "' .
an d at tI1c same tunc

o·1rcct Ilead lnJuncs
. . .

that result in fractures may occur during a motor vehicle accident, falls or assaults i.e.
direct strikes to head.

Fractures to the head can also occur at the base of the skull (Anterior fi.1ssa fractures).
An anterior fossa fracture inr.:re.:tscs damage to cranial nerves and vessels that result in
rhinorrhea or epistaxis (cerebrospinal fluid drainuge from the nose), periorbital
ecchymosis and anosmiil. (crnniol nerve one damage) or visual defects (cranial nerve two
damage). Injuries involving the middle car arc a result of

po~tcrior

foss..'lc fractures.

Fractures to the temporal petrous bone can result in blood drainage from the ear ~>J.
2.2.5.2. Dislocatinnsllnr.lircct I lead Injury
Indirect head injury involves injury to brain tissue as a result of severe whiplash or
··shaken baby synJromc"'. This form of trauma to the brain results in disruption of nave
cells and their axons leading to permanent brain damage or complications u5•

2.2.5.3. Contu5ions/Swclling/Di1Tusc Axonal injury
Diffuse axonal injury causes brain tissue damage that is often dillieult to detect and is
often the cause of indirect hc.:td injury. The

lll:n·c

cells located in grey matter of the

brain communicate with the white matter. axon nerve tracts. Sudden stretching, tw·isting
or jolting of these nerve tracts can lead to coma or brief loss of consciousness. Diffuse
axonal injury results in microscopic damoge to brain tissue that can not~ visualised on
Computer Tomograph (CT) or Magnetic Resonance Angiography (MRA) scans but
may appear on a Single Photon Emission Computed Tomography (SPEC!") scan ~.
6

21

2.2.5.4.11ypoxic/Anoxic Head Injury
The bmin weighs approximately 2% of our body weight, yet consumes 20% of the
body':; oxygen supply. Thacfon.:. the brain is more susceptible to injury if there is
insufli:-:ient oxygcn supply. Hypoxic brain injury is a decreased supply of oxygen to the
brain and anoxic hrain injury is thl! absolutl! lack of oxygen. lnju1y to the brain will
often set in alter a lack of blood llow to the brain and is also kno\.\'!1 as ischacmic insult

"'
The areas of the brain a!kctcd by rl.'duccd

oxyg~.,:n

supply include the cerebral and

cerebellar regions. in particular basal ganglia. Regions of the bruin that arc also
sensitive to lack of oxygen include the Purkinjc librcs of the cerebellum and

paricto~

.. I cortex anu' t I1!.~ h'1ppocampus 1'6.
occ1p1ta
2.2.5.5. Secondary '1\. . pcs or lle,1d Jnjuri{.'S
Secondary brain injury is often the result of the head being injured minutes, hours or
days a!ier the initial insult. The cause of this type of injury \Vill vary from intracranial
hacmatomas. intracranial infection, epilepsy and systemic hypoxia to hypotension. The
most common secondary brain injuries sustained by patients in this study are
intracranial haematomas.
2.2.5.6. Intracranial Hacmatomas
An intracranial hacmatoma is a localised collection of blood due to a tissue injury or
tearing of blood vessels. The Jura is membrane that covers the bmin and spinal cord.
Blood clots that develop between the skull and dura mater arc known us epidural
haemutonu.Js. A blood clot that develops hetwl!en the dura mater and the brain is called a
subdural haematoma ~ 0 •

There arc a number of intracranial hacmatomas identiJied in the brain all arising from
various physiological complications. Thl!sc haematomas may be located in various
regions of the brain: Frontal, parietal, temporaL occipitaL optic nerve, ccrcbe\la-pontinc
angle, brain stem, hypothalamic and pituit<Jry. posterior fossa 66 •

22

Only patients that sustained a closed skull fracture and a GCS between 14 & 15 (mild
TBI) 9 to 13 (moderate TBI) and a GCS < 9 (severe TBI) were used in this study, with
the majority having sustained a mild to moderate Tl31.

23

2.3. Pathophysiology of Head Injuries
Fundamental processes occur during bead injuries which can culminate in cell death.
These processes include the release of the excitotoxic amino acids, aspartate and
glutamate. production of free radicals. and increased levc\s of lactate and hydrogen ions.
The final pathway of the process involves the entry of calcium ions into the cells. which
results in cell swelling. S\\·elling \Vithin the cranium results in an increase in intracranial
pressure (ICP) and a reduction in ccrehral perfusion pressure (CPP =the mean arterial
blood pressure- intracranial pn.:ssurc). What follows is cerebral ischaemia and reduced
delivery of oxygen and glucose to the tissue, provoking further acidosis ami the n:lcase
of free radicals ~' 7 . Studies have shown that brain ischaemia is the predominant cause of
complicating traumatic hrain injury bM-?I_

2.3.1. Uypoxill and Hypotension in llcnd Injuries

Injury to the CNS in head trauma leeds to a chain of physiological events that lead to
secondary brain damage. lnsufticicnt oxygen supply to the brain after injury to the head
is kno\vn to result in tlclctcrious effects. Inadequate oxygen to brain tissue may occur
from arlt.::rial hypotension. low haemoglobin concentration and decreased oxygen
saturation. Most of these factors arc the result of secondary brain damage that occurs
from cxtracranial injuries. causing respiratory failure and blood loss
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The treatment of hypoxemia and hypotension often occur at the scene of injury.
Ventilation of the patient ensures th::n both hypoxemia and hypotension arc controlled
prior to patient arrival at hospital. A decrease in oxygen saturation of less than 90%
suggests the patient has reached a hypoxemic state, (oxygen saturation (P02) measures
of less than

(l()

mmllg arc dcfinl'd as hypoxic). Studies by Godwin el of (2005)

30

have

shown that bcnzodiazt.:"pincs nnd opioids used in sedation and analgesia increase the
patient's chances of developing hypoxemia. Chestnut et a/ ( \993)

73

reported that

hypoxia occurs in 45.6% of severely head-injured patients and has a signilicunt
influence on patient mortality.
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Hypotension is a lowering of blood pressure; a systolic blood pressure of less than 90
mm J-Ig. ~ 6 In a recent article Choi et al (2004)

74

found that doses of 0.2-0.3mg of

midazolam caused hypotension in 20% of intubated patil..!nts in a pr!.!hospital setting.

Rapid administration and increased doses of midazolam may also be associated with
hypotension

30

.

Many studies have

suggested

that midazolam causes arterial

hypotension. especially in elderly and haemodynamically comprised individuals
The biochemical

mechanisms

behind

midazolam-induccd hypotension arc not

completely understood. llowcvcr. discussion by Jones et a/ ( 1979)
( \984)

?H

77

and Reves et a/

suggest that the negative inotropic ciTccts. reduced vascular resistance n

reduced sympathetic activity

HI

74 76
' .

1111

or

may account for midazolam-imluccd hypotension.

Moreover other studies suggest that midazolam directly relaxes vessel tone and causes

"Jh ypotcns1on
·
artcrm

H27~8l

-' ·.

This study will examine the relationship between midazolam usc in a prehospital setting
for patients with head injuries. There will be particular focus on whether midazolmn
contributes to increased symptoms of hypoxia and hypotension.

There is a growing amount of literature that suggests midazolam contributes to
increased symptoms of hypoxia and hypotension in individuals. The study hy Chestnut

eta! (1993)

7

.1

clearly showeJ that hypoxia anJ hypotension lcnJ to an increase in

mortality of 50% in patients sullCring from severe head injuries. This raises an
important question: if midazolam contributes

1.1

increased hypoxia and hypotension in

patients, why is midazolam being administered to individuals \VIm have sustained head
injuries when hypoxemia and hypotension me common complicutions associated with
head injured patients'? Therefore, this study will be assessing whether midazolam dues
increase the symptoms of hypoxia and hypotension in patients with head injuries.
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2.3.2. Glasgow Coma Scnle Assessment for Traumatic Brain Injuries in the prchospiml
setting

Western Australian paramedics usc the Glasgow Coma Scale (GCS) to categorise the
severity of Traunwtic Brain Injury (fl31) in individuals. A mild TBI cnn include
fractures, Jaccrutions. abrasions or contusions. More commonly mild TBI patients
include loss of consciousness (LOC), amnesia, vomiting, headaches or changes in
mental swtus at the time of trauma (Figure 5). A GCS score of 13 to 15 is used to

A mild head injury is oltcn ~ubdividcd into categorises of low
. k·,med'mm ns
. k·or I11g
. I1 ns
. k 84 .
ns

categori:-.c a mild TBI

62

.

Mild TBI (GCS 14-15)

Low Risk
GCS 15 without LOC,
amnesia, vomiting or
headache

Moderate Risk
GCS 15 with any of
LOC,
amnesia, vomiting, or
headache

Flj.:urc 5. ,J!Rorithm of cul!');l!ries of,\ti/J /HI (CiCS)
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High Risk
GCSof14or15with
skull fracture and/or
neurological deficits

R"lm.!s

85

2.3.3. Patie-nt Assessment in the prchospilal setting

Any assessment of TBI management in a prehospital setting requires a valid tool. The
visual nnalogue scale (VAS) and verbal numerical response scale (VNRS) arc two vulid
assessment tools used by

param~dics

at StJohn Ambulance Service W.A. These tools

ensure a quick, simple, reliable and valid assessment of patient's injuries.
2.3.3.1. Visual Analogue Scale (VAS)

The visual analogue scale consists of a vertical or horizontal line. 1Ocm in length with
scale~

of no pain and worst pain at each end (Table 5). The respondents mark a point on

the line to represent the intensity or his or her pain. The VAS simplicity, reliability and
validity allow the puin assessment tool as an optimal device for describing pain levels
for patients x". The limitation surrounding the accuracy of the VAS tool is that some
individuals may be visually impaired. suffer from motor deficits or cognitive
impairment. This may occur particularly in elderly individuals or trauma cases. The
other limitution found with the VAS is the error rate within the scale of approximately
20mm

7
H•

wom.p11n

2.3.3.2. Verbal Numerical Response Scale (VNRS)

The VNRS has the bro<Jdcst application in the prehospital selling. Paramedics ask the
patient to describe the severity of their pain on a scale from zero (no pain) to ten (most
severe pain). The patients' level of pain is recorded and treatment is administered where
appropriate 87 .

Limitations surrounding both the VAS and VNRS tools arc that individual
interpretations of pain intensity and severity will vary slightly. llowevcr both these tools
are used for assessment of traumatic brain injury in a prehospital setting and nppropriatc
assessment is necessary to ensure effective treatment x<~.
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3. Methods
The patient cohort comprises retrospective data collected from (unidentified) patient
cmc records between January 2001 and February 2006 from the database at StJohn
Ambulance Service W.A. (sec appendix I -Patient Care Record sample sheet). Patient
care records for all cases that wer~ treated with midazolam and sustained a head injury
were used and compared to patient care records of cases that had sustained a head
injury. but did not receive midazolam. The patients that did not receive midazolam
(non-miduzo\am) for treutmcnt was lJscd as the control group in this study.

Ethical approval for the projed was given by Edith Cowan University Ethics
Committee. St John Ambulance Service W.A. also gave permission for the usc of
unidentified patient care n:cords to CP!lduct the research.

Physiological parameters were taken from p<Itient care records to assess whether
midazo\am inlluenccs hypoxia or hypotension in head injured patients and a comparison
of these physiological parmncters was made with patients who had sustained a head
injul}' and did not receive midazolam (sec appendix- 2).
The data parameters collected from patients care records for qunntitative multivariate
analysis inclw.lcd:

I. Age
2. Gender
3. Glasgow Coma Scale (GCS) which determines classification of head injury. Mild
Tl31 == 15 to 14 GCS. moderate TBI == 9 to 13 GCS and severe Tl31 ,._ < 9 GCS
4. Systolic Blood Pn.:ssurc [initia 1 rending (Sl3P 1) & final reading (SBP2)j
5. Pulse Rate per minute [initial reading (PR 1) & !ina\ reading (PR2)J
6. Respiration Rate p..:r minute [initial reading (RR I) & final reading (RR2)J
7. Oxygen Saturation in mm llg [initial reading (Pa0 2 1) & llnal reading (Pa012)]

Each physiological parameter SBP\, PRL RIO and Pa0 2 1 was recorded by paramedics
on arrival at the scene during initial assessment of patient and prior to administration of
midazolam or fi.1r the nun-midazolam cases (control group) paranu:h..•rs were recorded
by panuncdics on arrival at the scene during initial assessment of the patient The !ina\
reading for each physiological parameter, Si3P2. PR2, RR2. Pa012. was recorded by

2R

paramedics approximately 5-\0 minutes ailer initial administration of miJazolmn or for
the non-midazolam cases upproximatcly 5-l 0 minutes after initial assessment.

llypotension in the individual was determined after midazolam administration where
:;ystolie blood pressure (SUP) decreases to 90 nun 1\g or less \Vitb an initial SBP greater
than 90 mmllg. Other variables considered includ!.! where a further decrease in SBP of 5
mmllg or more in patients is observed with an initial SI3P higher than 90 mmllg. Where
SBP cannot be obtained other indicators of hypotension (decreased pulse rate and
respiration rate) wen: tabu\nted and examined.

To determine whether a patient has reached a hypoxemic stale, pulse oximetry is used to
measure oxygen saturation. A decrease in oxygen saturation or less than 90% suggests
the patk.nt has reached a hypoxemic state
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.

Readings of less than 60 P02 mml-lg will

designate hypoxia. Where readings of oxygen s:Huration cannot be obtuined, respiratory
distress in the patient was tabulated and utilised for this study.

Statistical comparisons of the parameters \Vcre undertaken using the Statistical Package
for the Social Sciences (SPSS) sofhvare version 14 (SPSS

lncorporat~.:d

Inc.). Analyses

were conducted on the study population and subsequent analysis was conducted by
dividing the study population into categorie-s of gender (mule and female). age (less than
35 years and over 35 yeurs) and head injuries (mild Till,

mod~.:ratc

TBI and severe TI31).

Data was inserted into the SPSS spread sheet \'lith the following parameters recorded:
age. genJcr, category of TBI. wh~.:thcr patients had received treatment of midazohun or
no trcatnwnt, putients systolic blood pressure readings prior to treatment (initial
reading). patients systolic blood pressure uftcr trcutment (linal reading). For the patients
that did not receive tn::atnwnt the initial readings were recorded as initial and tina\ PaCh
reading. initial and tina! pulse rate readings. initial amllinal respiration rail! r~.:adings.

A box plot test was

us~.:d

to determine normality between physiological data sets (sec

appendices 3 to 30). All data was normally distributed, hence lndepcndl!nt Sample
Tests. Le\"l!nes"s Test for Equultty of Variances and Paired Sampll! T-Test comparisons
\VCre used to determine stutisticul significance between pairs of physiological
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parameters; Sl3Pl-Sl3P2. PR l-PR2. RR l-RR2 and Pa0 2 l-Pa022. Additional analysis
was conducted on mild TBI, modl.!ratc
Studcttl<; t-test.

Signi!i~anee

rm

and severe TI31 using Mil:rosoll Excel

was determined with one-tailed distribution and paired two-

sample equal/unequal variance.

The main limitation of the study was the dilli~ulty in obtaining prc-midazolam
physiological measures from treated patients. Where a patient is uncontrollable or
aggressive. obtaining measures

or pulse rate, blood pressure or oxygen saturation values

is extremely diflicu\t if not impossible. In a situation like this the puramedics' primary
concern is to sedate the individual so no further injury to the patient or anyone else
occurs. Therefore records of puticnts' initial physiological measures, immediately prior
to the administration

or

midazolam. muy result in restricted data validity. Anothl.!r

limitation was incompktc patient care records. Limiting the study to complete patient
care records i1wluding the above criteria sewrely restricted the number of cases for the
study and minimised the study population from 4500 to 96 .

.10

3.1. Methods for AnHI,ysis of Results
The unalysis conducted in this study included the following:
1. An analysis of \'·.'hcthcr midazol::m1 inllucnccs hypotension in patients with a head
injury. The physiological parameters used to determine symptoms of hypotension arc
systolic blood pressure. respiration rate and pulse rate.

2. Analysis ofwhctht.·r midnzolam inlluenees hypoxia in patients with a head injury \vas
determined by using the physiological parameter oxygen saturation.

The approaches used to determine these outcomes were:

a) A statistical comparison between the initial reading for midazolam and nonmidazolam \vas conducted. The variables used to determine whcthcr thcre is a
significant difference bctwccn initbl midazolam and initial non-midazolam are: systolic
blood pressure (SBP I). respimtion rate (RR I) and pulse rate (PR I).

b) An analysis for significant difference between the initial and final SBP l-SBP2, RR 1RR2 and PR I-PR2 readings for the midazolam cohort.

c) An analysis for signilieunt dir!Crence bctwecn the initial and final SBP1-SBP2, RR1RR2 and PRI·PR2 readings for the non-midazolarn cohort.

d) A cnmparislln of the statistical signiticant diiH::rencc for the final SI3P2, Pa022, PR
and RR reaJings between the midazolam and non-midazolam cohorts.

c) An analysis for signiliL'ant difference between b) und c) wus conducted. Is there is
signilicant dilll:rencc between the initial and linal rcaJings for midazolam compared to
the initial and tina! readings for thc non-mid<lzolam cohort.

3\

3.1.1.1,:tticnt cohorts

The study population includes a total of 96 patients. The m~jority of patients had
susl<tined a mild to moderate heud injury. The study population included a total of 56
patients with a mild TBL 25 puticnts with a moderate TBI and 15 patients categorised as
su!Tering from scwrc TBI (Table 5). Of the 96 patients, 49 received midazolam li1r
st:dating puip~,:~cs and 4 7 patients wert: not treated with midazolam. The 4 7 patients not
treated with mklazolam were used as the control group.

T:1blc 5. Number of cases for each catl.!gory of Tl3\ for midazolam and
non-midazol·tm
' cohorts
Mild Tl31 Moderate TUI Severe TBI Total

19

16

14

49

38.8%

32.7%

2R.6%

100%

non-rniduzolam

37

9

I

47

(control)

78.7%

19.1%

2.1%

\00%

Total

56

·'
26%

15

96

midazolam

,-

58.3%

15.6%

100%1

The total number of males and females for the study included 52 malt:s and 44 females.
The number of males and females in the study population for the midazolam cohort
consisted of 34 males and 15 females. In the non-miduzolam cohort there were a total of
18 males and 29 femule<: (Tublc 6).

Table 6. The number of nnlt:s
'
'·md females in the studv population
male
female Total

]4

15

49

69.4%

30.6%

1()() %

non-111 idazolam

18

29

47

(control)

38.3%

61.7%

100%

Total

52

44

96

54.2%

45.8%

100%

midazolarn

--cc·--·
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The number of cases in each age group is provided in table 7. Fur the midazohun cohort
the majority of patients were between the ages of 16-25yrs (21.3%), 26-JSyrs (27.7%)
and 36-45yrs (23.4%). In the non-midazolam cohort, the majority of patients (38.3%)
\vcre 66yrs and older. There were two pntients where the age group was not n.:corded by
paramedics.

Ta bl e 7 . t\_gc

,_

I
midazolam

non-midazolarn
(control)
total

I"
Dt.::mo~r~lliCS

II·

16-

26-

I Ovrs
0

15vrs
0

25\'TS

35\T~

10

11

0%

0%

21.3%

27.7%

I Stu dv Poru Iat1on
.
ol. 11e,
56364645

66yrs

65vrs

older

ll

5

I

7

47

23.4%

10.6%

2.1%

14.9%

100%

- - - '--;-·

I

2

9

5

J

2

7

1.1%

4.3%

19.1%

10.6%

6.4<Vo

4.3%

14.9%

I

2

19

18

14

7

8

_,,.

1.1%

2.1%

20.2%

19.1%

]t\.9%

7.4%

8.5%

26.6%

33

Total

55vrs

'TS

18

47

38.3%

lOO"l'o

94
1()()%

4.0. Results
4.1 Analysis of Midazolam/Non midazolam cohorts
4.1.1 Statistical analysis of systolic blood pressure

BLOOD PRESSURE (SBP)
140 ~~~~~==~~~~~~~~~

135
130
a. 125
ID
(J) 120

1----~---r-~~~~~~~

j. midazolam

!--=~

~ no midazolam

115
110
105
Initial Reading

Final Reading

MEANS

Figure 7. Means and Standard Error ofBlood Pressure (SBP) for midazolam and nonmidazolam groups

Table 8. SBP summary of means ± SE for midazolam and non-midazolam cohort
Initial Reading Final Reading Mean decrease Sig.
(SBPl)
(SBP2)
(SBP 1-SBP2)
(p)
5.5 ± 2.45
0.029
Midazolam (n = 49)
123 ± 3.4
117 ±3.5
no midazolam (n = 47)
130 ± 4.4
128 ± 3.9
2.2 ± 0.86
0.015
Error bar = ± SE (Standard Error) of the mean

The mean decrease between SBP1-SBP2 in patients for the midazolam cohmt is 5.5 ±
2.45, compared to a mean decrease of 2.2 ± 0.86 in SBP 1-SBP2 for the non-midazolam
cohoti. When comparing the statistical differences between these means there is no
statistical significance between the mean SBP} ecrease of the midazolam cohort to the
mean SBP decrease of the non-midazolam cohort.

a) When a comparison was made to determine whether a significant difference was
present between the initial SBP for the midazolam and non-midazolan1 cohotts (not
shown in table format); p = 0.150 (as calculated by the SPSS Levene' s Test for equality
of variances). When p< 0.05 there is a statistical significant difference between these
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groups. lienee, then! is no signilicant difference between the initial SUP readings for
midazolam and nmHnidazolam cohorts.

b) WhL"n comparing the signilicant di!Tcrencc between the initial and final SlW reading
for the midawlam cohorts; p

=

0.029. When p< 0.05 there is a statistical signiticant

difference between these groups. In this c<.t:-.c there is a statistical signiiicnnt difference
between the initial reading (SI3Pl) and !ina\ rcadi~1g (SBP2) for the midl'zolam cuhorts.
The tirllll SUP reading is signilicantly (p < 0.05) lower than the initial SBP reading.

c) When comparing the significant dillCrcncc \x.'t\Vt.."Ctl the initial and tina\ SBP reading
for the non-midazolam cohort; p == 0.015 when p< 0.05 there is statistical di rrl'rcnce
bet\vcen these groups. In this case there is a statistical signilicant dilfcrence between the
initial reading (SBPl) and final reading (SBP2J for the non-midazolam cohorts. The
tina\ reading is signilicantly {p < 0.05) lower tlum the initial n:ading.

d) When comparing the statistical signilieant difference for the final SBP reading
between the midazohun and non-midazolam cohorts; p == 0.035 \vhen p < 0.05 there is a
signi!icanl di!TerL'llCL' between the two groups. Therefore. there is a signilicant {p <
0.05) difference bt.:twecn the tina\ SBP reading \()r the midazolam and non-midazolam
cohorts.

c) When a comparison \Vas made between the diiTcrences for SBP\-SBP2 for the
midazolam and non-midazolam cohorts i.e. the statistical di!Terence bcl\vecn the
diJTerenccs p "" 0.(l76; when p > 0.05 there is no statistical significance between the
initial and tina! SBP rcuding bct\vccn the midazolam and non-midazo\am cohorts. i.e.
there is no stutistical signilicant di!Tcrencc between the di!Tcrcnccs b) und c).
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4.1.1. Statistical Analysis of Oxygen Saturation (Pa02 )

. - - - - - - - -- - - -- - - - - -OXYGEN SATURATION (Pa0 2 )

-

-

- - ---,

• midazolam

c no midazolam

initial Reading .

Final Reading

MEANS
Figure 8. Means of Oxygen Saturation/or midazolam andnon-midazolam groups
Table 9. Pa02 summary of means ± SE for midazolam and non-midazolam cohort.
Initial Reading Final Reading Mean increase
Sig.
(p)
(Pa02l- Pa0 22)
(Pa02l)
(Pa0z2)
rnidazolam (n = 49)
95.3 ± 0.7
97.1 ± 0.5
1.8 ± 0.472
0.000
no midazolam (n = 47)
96 ± 0.5
98.7 ± 0.2
2.6 ± 0.443
0.000
Error bar =± SE (Standard Error) of the mean
The mean Pa02 increase for the midazolam cohort is 1.8 ± 0.472 after treatment with
midazolam. The treated patients mean Pa0 2 readings do not reach 98%. For the nonmidazolam cohort there is a 2.6 ± 0.443 increase in Pa02. Both midazolan1 and no
midazolam patients received oxygen supplementation during treatment.

When

comparing the statistical differences between these means there is a statistical
significance between the mean Pa02 increase of the midazolam cohort to the mean
Pa0 2 increase of the non-midazolam cohort.

a) When comparing the significant difference between the initial Pa02 for both
midazolarn and non-midazolarn cohorts (not shown in table format) ; p = 0.394 (as
calculated by the SPSS Levene' s Test for equality of variances). When p > 0.05 there is
no statistical significant difference between these groups. Therefore, no significant
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difference between the initial Pa0 2 readings for midazolam and non-midaw\am cohorts
was seen.

b) When comparing the .significant dilTercncc between the initial and final Pa02 reading
for the midazolam cohorts; p

=

0.000 \Vhen p< 0.05 there is a statistical significant

diOCrence between theses groups. In this case there is a statistical signiticant dif!Crcncc
between the initial n.:ading (Pa<hl) and tina\ rcad.ing (Pa0 22) for the midazolam
cohorts. The tina\ reading is si.;;.nificant\y (p < 0.05) higher than the initial reading.

c) When comparing the signilicant difference bct\\'Cl'll the initial and tinall'a0 2 reading
for the non-midazolam cohort: p == 0.000 when p< 0.05 there is statistical

diff~rencc

between these groups. In this case there is a statistical significant differ..::ncc between the
initial reading (Pa0 2 1) and !ina\ reading (Pa0 22) for the non-tnidawlam cohorts. The
final reading is signilh:antly (p < 0.05) higher than the initial reading.

d) When comparing

th~

statislical significant difference for the final Pa0 2 reading

between the midazolam and non-miJazolam cohorts. Using Independent Samp!C's TTcst, Len:nc 's test tOr Equality of Variance. equal variances assumed. p == 0.0 I 0 when p
< 0.05 there is a significan! difli:rence between the two groups. Therc!'ore. there is a

significant (p < 0.05) difference between the final Pa0 2 reading for the midnzolam and
non-midazolam cohorts.

c) A statistical comparison between Pa02 1-Pa02 2 mitlazolam ar,d Pa0 21-Pa0 22 nonmidazolam cohorts; p

=

0.009 when p < 0.05 there is a !'itatistical significance between

the initial and tina\ Pa02 reading between the midazolam and non-midazolam cohorts.
i.e. there is a statistical significant difference between 1he differences b) ami c).
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-4.1.3. Statistical Analysis of Respiration Rate
-
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RESPIRATION RATE (resp/min)
30 ~--~~~~--~~~~~~~~

25
c: 20

E

c.
e

• m idazolam

15

f/)

10
5
0
In itial Reading

Final Reading

MEANS

Figure 9. Means of Respiration Rate fo r midazolam and non-midazolam cohorLs
Table 10. Respiration Rate sum mary of means ± SE for mida:z;olam and non-midazolam
cohort.
Initial Reading Final Reading Mean decrease Slg.
(RR1)
(RR2)
(RR1-RR2)
(p)
2.5 ± 0.929
(n = 49)
23.8 ± 1.0
midazolam
2 1.3 ± 1. 1
0.009
no midazolam (n = 47)
19.4 ± 0.5
18.9 ± 0.4
0.425 ± 0.171 0.017
Enor bar = ± SE (Standard Error) of the mean
The mean decrease for the midazolam cohort is 2.5 ± 0.§>29 resp per mm after
midazolam administration. Whereas, the mean decrease for the non midazolam cohort is
0.425 ± 0.171 resp/min with no treatment administered. When comparing the statistical
differences between these means there is no statistical significant difference between the
m ean RR decrease for the m idazolam cohort to the mean RR decrease for the nonmidazolam coho11.

a) When comparing the statistical significant difference for initial Respiration Rate
(RR1) between midazolam and non-midazolam cohorts (not shown in table format); p =
0.000 (as calculated by the SPSS Levene' s Test for equality of variances). When p <
0.05 there is a statistical significant difference between the groups. In this case there is a
significant difference between the initial RRl readings for midazoJam and the initial
RRl reading non-midazolam cohorts.
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b) Wh~n comparing the significant diff~renc~ bctw~~n the initial and final RR reading
for the midazolam cohorts; p

=

0.009 when p< (J.05 there is a statistical signilicant

ditli:rcnL'l:' hl'tWCL'n the groups. In this case tberl' is a statistical signilicant di!Tercncc
lletwc~n

the initial rL·ading (RRl) and finn! reading (RR2) for the midazo!am cohorts.

"lltc final reading is signilicantly (p < 0.05) lower than the initial reading.

c) When comparing th~.: signilicmtt dillCrcncl' hL'IWL'Cit the initial and Jinal RR reading
for the noJHttidal.lllam cohort: p
bi..!tWcen the groups. In this

C<.LSC

=

0.017 \\hen p< 0.05 there is a statistical di!Terencc

there is a statistical signilieant dirti:rL·ncc hl'twecn the

initial rl..!ading (\{R I) and lina! reading tRR~) li.1r the non-miduznhun cohorts. The finn!
reading is signilicantly tp < {l.05) lmH:r than the initial rl..!mling.

d) \\'hen cnmpanng the statistical signilicant difti:n.:nce for
bd\\cen the rnidawlam and non-midazolum cohorts; p

=

th~

tina\ RR rt:ading

0.064 when p > 0.05 there is

no signilicunt dilll:n:n~o:t: h.:twecn the two groups. Therci!Jrl..!. there is no signilicant (p >
0.05) dirtCr.:ncc hctwccn the tina\ (RR2) rt:ading for the midazolam and tina\ {RR2)
reading fur non-midaw\am cohort.

c) When comparing the di!Terl..!nces bctwel..!n RR I-RR2 midazo!am and RR l-RR2 non·
miJazolam CllhOriS" p

=

0.3\6 \\hen p > 0.05 there is no Statistical signilicance between

the initial and Jinal RR rl.'ading het\ve~n midazolum and non-midazolum cohorts. 1.e.
there is no stmistical signilicant difll:rcm.:c between the di!Tcrcnces b) and c).
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4.1.4. Statistical Analysis of Pulse Rate

PU LSE RATE (beats/min)
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Figure 10. Means ofPulse Rate for midazolam and non-midazolam cohorts
Tab!e 11 P u1se R a te summary o f means ± SE£or nu'dazo am_and non-m1'd azo am cohort
Initial Reading Final Reading Mean decrease sig.
(p)
(PR2)
(PR1-PR2)
(PR1)
1.7 ± 1.7
0.338
Midazolam (n = 49)
98.1 ±2.7
96.4 ± 3.1
1.1 ± 0.8 14
0.173
no midazolam (n = 47)
88.1 ± 2.2
86.9 ± 2.2
Error bar =± SE (Standard Error) of the mean
The mean decrease in pulse rate (beats/min) for the midazolam cohmt is 1.7 ± 1.7 after
midazolam administered. Whereas, the mean decrease in pulse rate for the nonmidazolam cohort is 1.1 ± 0. 814. When comparing the statistical differences between
these means there is no statistical significant difference between the mean PR decrease
for the midazolam cohmt to the mean PR decrease for the non-midazolam cohmt.

a) When comparing the significant difference between the initial Pulse Rate (PR) for
both midazolam and non-midazolam cohorts (not shown in table format); p = 0.006 (as
calculated by the SPSS Levene's Test for equality of variances). When p < 0.05 there is
a statistical significant difference between the groups. In this case there is a significant
difference between the initial PR readings for midazolam and initial PR for nonmidazolam cohorts.

b) When comparing the significant difference between the initial and final PR reading
for the midazolam cohorts; p = 0.338 when p > 0.05 there is no statistical significant
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difference bct\vccn the groups. In this case there is no statistical signiJkunt diffcn:ncc
between the initial reading (PR I) and tina\ reading (PR2) for the midazolam cohorts.

c) When comparing the signiticant dilli::rcncc between the initial and Jinal PR reading
for the non-midazolam cohort: p == 0.173 v.'hen p > 0.05 there is no statistical di!Tercncc
between the groups. In this case there is no statistical signilicant difference between the
initial reading (PR I) and !ina\ reading (PR2) forth\.' non-miduzolam cohorts.

d) When comparing the statistical significant di!Tcrence between the final PR reading
for the rnidazolam and non-midaznlam cohorts; p = 0.014 when p < 0.05 there is a
signilicant dif!Crenee between the two groups. Therefore, there is a significant (p <
0.05) diiTcrent:e between the final PR reading for the midazolam and ncm-midazolam
cohorts.

c) When companng the JillCrcnccs li.1r I'R between midazolam and non-midazolam
cohorts: p

=

0.939 when p > 0.05 there is no statistical signilicuncc bct\vecn the initial

and final PR reading between the midazolam and non-midazolam cohorts. i.e. there is
no statistical signilicant diJTercncc bchvecn the Jiffercnccs h) and c).
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4.2. Analysis of Gender & Midazolam/Non-midazolam
4.2.1. Statistical analysis of gender vs. systolic blood prcssu•·e

Gender vs. Systolic Blood Pressure (SBP)
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Figure 11. Means ofBlood Pressure (SBP) for males and females
Ta bl e 12 S;ystor1c Bl00dP ressure summary of means and ± SE fior gen der
a) Ini tial SBP
Gender vs.
Systolic Blood
Reading
+M & -M
Press ure
(SBP)

MALES
n=52

FEMALES
n=44

b) Difference c) Difference
between
between
Initial & Final Initial & Final
SBP reading
SBP readiJlg
-M
+M
l = 122.7
1 = 126.5
SE± 3.44
SE± 4.67
F = l15.5
F = 125.8
SE±3.56
SE±4.32
Mean decrease Mean decrease
0.72 ±3.28
7.2 ±3 .28
p = 0.709
p = 0.035
yes significant no signjficance

e) Statistical
d) Final SBP
Differe nce
Reading
between b) & c)
+ M&-M

+M = 122.7
+M = IJ 5.5
SE ±3.44
SE ±3.56
-M = 126.5
-M = 125
SE ±4.67
SE ±4.32
p = 0.079
Mean
no significance
Mean
difference
difference
10.3 ±5.83
3.82 ±5.8
p = 0.514
p = 0.083
no significance
no significance
+M= 123.3
I = 123.3
I = 133.6
+M = 12 1.8
SE ±8.15
SE± 8.1 5
SE± 6.52
SE±8.33
F = 12 1.8
-M= 133.6
F = 130.5
-M =130.5
SE±6.51
SE ±8.33
SE±5.85
SE ±5.85
p = 0.798
Mean
Mean decrease Mean decrease
no significance
Mean
difference
3. 1 ±1.23
difference
1.5 ±2.7
10.29±10.8
10.3 ±5.83
p = 0.018
p = 0.579
no significance yes significant
p = 0.346
p = 0.393
no significance
no significance

+M = mtdazolam
-M = no midazolam
I = initial reading
F = fi nal reading
p = significance value
SE± = Standard error mean
M = males
F = females
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4.2.2. Statistical analysis of gender vs. oxygen saturation
Gender vs. Oxygen Saturation (Pa02)
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Figure 12. Means of Oxygen Saturation for males and females
Table 13. Oxygen Saturation summary of means and ±SE for gender cohort
Gender vs.
Oxygen
Saturation
(Pa02)

MALES
n=52

FEMALES
n=44

a) Initial Pa02 b) Difference c) Difference
between
between
Reading
Initial & Final lnitial & Final
+M &-M
Pa02 reading Pa02 read ing
+M
-M
+M =95. 1
I = 95.1
I = 96.9
SE ± 0.789
SE±0.789
SE± 0.661
F = 97
F = 98.6
-M =96.9
SE ±0.661
SE ±0.665
SE±0.269
Mean difference Mean increase Mean increase
1.74 ± 1.18
1.88 ±3.71
1.72 ±0.5 16
p = 0.149
p = 0.006
p = 0.006
no significance yes s ignificant yes s ignificant
+M =95.7
I = 95.7
l = 95.5
SE±1.33
SE ± 1.33
SE ± 0.653
-M =95.5
F = 97.5
F= 98.7
SE ±0.654
SE±0.955
SE±0.202
Mean difference Mean increase Mean increase
0.2 16 ±1.31
3.24 ±0.625
1.8 ±0.579
p = 0.870
p = 0.008
p = 0.000
no significance yes significant yes significant

+M = midazo lam
-M = no midazolam
1 = initial reading
F = fmal reading
p = significance value
SE± = Standard error mean
M = males
F = females
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e) Statistical
d) Final Pa02
Reading
Difference
between b) & c)
+M&-M

+M =97
SE±0.666
-M =98.6
SE ±0.269
p = 0.343
Mean di fference no significance
1.58 ±0.939
p = 0.033
yes sign ificant
+M =97.5
SE±0.955
-M =98.7
SE ±0.202
p = 0.798
Mean difference no signjficance
1.22 ±0.977
p = 0.343
no significance

4.2.3. Statistical analysis of gender vs. respiration rate

Gender v s. Respiration Rate (RR)
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Figure 13. Means ofRespiration Rate for males and females
Table 14. Respiration Rate summary of means and ±SE for gender
Gender vs.
Respiration
Rate (RR)

a) In itial RR
Reading
+M &-M

b) Difference
c) Di fference
d) F inal RR
e) Statistical
between
between
Reading
Difference
Initial & Final Initial & F inal
between b) & c)
+M& -M
RR reading
RR reading
+M
-M
I = 19.9
+M =20.4
I = 23.1
SE ± 1.09
SE± 0.766
SE±0.963
F = 20.4
F = 19.4
-M =19.4
SE ±0.963
SE ±0.755
SE±0.755
p = 0.479
Mean decrease Mean decrease Mean difference no significance
2.71 ±0.942
0.444 ±0.304
0.997 ± 1.22
p = 0.007
p = 0.163
p= 0.41 9
)'es s ignificant no significance no significance

+ M =23.1
SE ±1.09
-M = 19.8
MALES
SE ±0.766
n=52
Mean
diffe rence
3.26 ±5.93
p = 0.01 8
)'es significant
+M =24.4
I = 25.4
+M =23.3
I = 19.1
SE ±2. 14
SE ± 2. 14
SE± 0.608
SE ±3.09
-M = 19. 1
F = 23.3
F = 18.7
-M =18.7
FEMALES
SE ±0.608
SE ±3.09
SE ±0.5 18
SE ±0.518
p = 0.439
n=44
Mean
Mean decrease Mean decrease Mean d ifference no significance
d ifference
2.13 ±2.22
0.41 5 ±0.208
4.57 ±2.32
6.29 ± 1.74
p = 0.353
p = 0.056
p = 0.165
p = 0.012
no s ignificance no significa nce no signi ficance
ly_es sionificant
+ M = m1dazolarn
-M =no midazolam
I = initial reading
F = fina l reading
p = significance value
SE± = Standard error mean
M = males
F = females
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4.2.4. Statistical analysis of gender vs. pulse rate

Gender vs. Pulse Rate (PR)
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Figure 14. Means of Pulse Rate for males andfemales

Table 15 P u1se Rate summary of means and ± SE flor_g_en der
Gender vs.
Pulse Rate
(PR)

a) Initial PR
Reading
+ M & -M

+M = 103.8
SE ±3.03
-M =87.2
MALES
SE ±3.88
n=52
Mean difference
16.7 ±5.03
p = 0.002
ves sionificant
+M =85.2
SE ±4.28
-M =88.7
SE±2.76
FEMALES
n=44
Mean difference
3.46 ±4.92
p = 0.486
no significance
+M = nudazolam
-M = no midazolam
I = initial reading
F = final reading
p = significance value
SE± = Standard error mean
M = males
F = females

b) Difference
between
Initial & Final
PR reading
+M
1 = 103.8
SE ± 3.03
F = 101.3
SE ±3.62
Mean decrease
2.53 ±2.02
p = 0.218
no significance
I = 85.2
SE ± 4.28
F = 85.5
SE ±5.16
Mean increase
0.267 ±3.39
p = 0.938
no sig nificance

c) Difference
between
Initial & Final
PR reading
-M
1= 87.2 ·
SE ± 3.89
F = 85.3
SE±3.79
Mean decrease
1.88 ± 1.21
p = 0.136
no significance
I = 88.6
SE ± 2.8
F = 88.0
SE ±2.65
Mean decrease
0.655 ± 1.09
p = 0.554
no significance
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d) -Final PR
Reading
+M&-M

e) Statistical
Difference
between b) & c)

+M =20.4
SE±0.963
-M = 19.4
p = 0.952
SE ±0.755
Mean difference no significance
0.997'± 1.22
p = 0.007
yes significant
+M =20.4
SE ±0.963
-M = 19.4
p = 0.847
SE ±0.755
Mean difference no sign ificance
0.997±1.22
p = 0.630
no significance

4.3. Analysis of Age & Midazolam/Non-midazolam
4.3.1. Statistical analysis of age vs. systolic blood pressure

Age vs. Systolic Blood Pressure (SBP)
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Figure 15. Means of Systolic Blood Pressure for age categories
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Table 16. Systolic Blood Pressure summary of means and ±SE for age categories
Age vs.
Systolic
Blood
Pressure
(SBP)

a) Initial SBP
Read ing
+M &-M

+M = 121. 1
SE ±4.63
-M = 120.8
<35yrs
SE ±4.23
n=40
Mean difference
0.248 ±6.5
p = 0.970
no significance
+ M = 125.9
SE ±5.28
-M = 136.6
>35yrs
SE ±6.27
n=54
Mean difference
I 0.65 ±8.46
p = 0.2 14
no significance
+M = m1dazo lam
-M = no midazolam
I = in itial read ing
F = fi nal read ing
p = significance value
SE± = Standard error mean

b) Difference
between
Initial & Final
SBP reading
+M
1= 121.1
SE ± 4.63
F = Jl 4.9
SE±4.07
Mean decrease
6.2 ±2 .52
p = 0.022
yes significant
I = 125.9
SE± 5.28
F = 120.4
SE±6.08
Mean decrease
5.5 ±4.34
p = 0.2 18
no significance

c) Differe nce
between
Initial & Final
SBP reading
-M
I = 120.9
SE ± 4.23
F = 118
SE ±4.05
Mean decrease
2.88 ± 1.06
p = 0.0 15
yes significant
I = 136.5
SE± 6.27
F = 134.7
SE ±5.48
Mean decrease
1.8 ± 1.22
p = 0.151
no significance
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d) Final SBP
Reading
+M&-M
+M = I 14.9
SE±4.06
-M = 118
SE ±4.06
Me,an difference
3.09 ±5.88
p = 0.603
no significance
+M = 120.4
SE ±6.08
-M = 134.8
SE ±5.48
Mean difference
14.3 ±8.19
p = 0.086
no significance

e) Statistical
Difference
between b) & c)

p = 0.253
no sign ificance

p = 0.194
no significance

4.3.2. Statistical analysis of age vs. oxygen saturation

Age vs. Oxygen Saturation (Pa02)
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Table 17 0 xygen saturatwn summary o f means and ± SE flor age categones
b) Difference
between
Initial & Final
Pa02 reading
+M
+M =96.2
I = 96.2
SE±0.83 1
SE± 0.83 1
-M =98. 1
F = 97.4
SE ±0.358
SE±0.6 15
<35 yrs
Mean difference Mean increase
n=40
1.88 ±0.036
1.2 ±0.426
p = 0.046
p = 0.009
yes significant yes signi fi cant
+ M =94.5
I =94.5
SE ± 1.11
SE ± l.ll
-M =94.9
F = 96.8
SE±0.642
SE ±0.936
>35 yrs
Mean di fference Mean increase
n=54
0.400 ± 1.22
2.29 ±0.842
p = 0.745
p = 0.012
no s ignificance ves s ionificant
+M = midazolam
-M = no midazolam
I = initial reading
F = final reading
p =significance value
SE± = Standard error mean
Age vs.
Oxygen
Saturation
(Pa0 2)

a) Initial Pa02
Reading
+M &-M

c) Difference
e) Statistical
between
d) Final Pa02
Reading
Difference
Initial & F inal
+M & -M
between b) & c)
Pa02 reading
-M
+M =97.4
I = 98.1
SE± 0.358
SE ±0.6 15
-M =99. 1
F = 99. 1
SE ±0.168
SE ±0.168
Mean increase Mean difference
p = 0.170
1.06 ±0.290
1.73 ±0.732
p = 0.024
no significance
p = 0.002
yes significant yes significant
I = 98.1
+M =96.8
SE ± 0.358
SE±0.936
-M =98.5
F = 99.1
SE ±0.223
SE ±0.168
Mean increase Mean difference
p = 0.042
3.56 ±0.290
1.67 ±0.963
yes sign ificant
p = 0.000
p = 0.094
ves significant no significance
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4.3.3. Statistical analysis of age vs. respiration rate

Age vs. Respiration Rate (RR)
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Figure 17. Means ofRespiration Rate for age categories
Ta ble 18 Resp1raf1011 Ra t e summary o f means and±SE£or age cate:gen es
Age vs.
Respiration
Rate (RR)

<35 yrs
n=40

>35 yrs
n=54

a) Initial RR
Reading
+M & -M
+M =24.4
SE ± 1.40
-M = 19.5
SE ±0.758
Mean
difference
4.86 ± 1.59
p = 0.005
ves s ignificant
+M=23
SE ± 1.49
-M =19.3
SE ±0.61 6
Mean
di fference
3.75 ± 1.61
p =0.027
yes significant

b) Difference
between
Initial & Final
RR reading
+M

c) Difference
between
Initial & Final
RRreading
-M

d) Final RR
Reading
+M& -M

e) Statistical
Difference
between b) & c)

I = 24.4
I = 19.5
+M =2 1.7
SE ± 1.40
SE ± 0.758
SE ± 1.00
F = 21.8
F = 19.2
-M = J9.2
SE ± 1.00
SE ±0.768
SE ±0.768
Mean decrease Mean decrease Mean difference
p = 0.671
0.352 ±0.308
2.6 ±1.27
2.61 ± 1.27
no significance
p = 0.052
p = 0.269
p = 0.047
no significance no significance yes significant
+M =21.1
I = 19.3
I = 23. 1
SE ± 1.49
SE ± 0.616
SE ±2. 16
F = 2 1.1
-M = 18.8
F = 18.9
SE ±2.16
SE ±0.522
SE ±0.522
Mean decrease Mean decrease Mean difference
p = 0.1 77
1.95 ± 1.34
2.26 ±2.22
0.466 ±0.207
no significance
p = 0.158
p = 0.032
p = 0.320
no sign ificance yes s ignificance no significance

+M = m1dazolam
-M = no midazolam
I = initial reading
F = final reading
X. = mean
p =significance value
SE± = Standard eiTor mean
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4.3.4. Statistical analysis of age vs. pulse rate

Age vs. Pulse Rate (PR)
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Figure I 8. Means ofPulse Rate for age categories

Table 19. Pulse Rate summary of means and ±SE for age categories
b) Difference
between
Initial & Final
PR reading
+M
+ M = 103.3
[ = 103.3
SE ±4.62
SE± 4.62
-M =92.3
F = 29.6
<35 yrs
SE ±2.97
SE±4.67
n=40 Mean difference Mean decrease
10.9 ±5.5
3.65 ± 1.72
p = 0.054
p = 0.045
no significance xes significant
+M =92.7
I = 92.7
SE ±3.0 1
SE± 3.0 1
-M =85.7
F = 93.9
SE±3.02
SE ±4.54
>35 yrs
n=54 Mean difference Mean decrease
7.05 ±4.32
1.16 ±2.83
p = 0.109
p = 0.684
no significance no significance
+M = m1dazolam
-M = no midazolam
I = initial reading
F = final reading
p = significance value
SE± = Standard error mean
Age vs.
P ulse
Rate
(PR)

a) Initial PR
Reading
+M & -M

c) Difference
e) Statistical
between
d) Final PR
Diffe rence
Reading
Initial & Final
between b) & c)
PR reading
+M&-M
-M
1 = 92.3
+M =99.6
SE ± 2.97
SE ±4.67
-M =89.6
F = 89.6
SE ±3 .30
SE ±3 .30
Mean decrease Mean difference
p = 0.814
2.64 ±1.16
9.96 ±5 .7
no significance
p =0.090
p = 0.037
xes significant no sig nificance
+M =93.9
I = 85.7
SE ±4.54
SE± 3.03
F = 85.4
-M =85.4
SE ±2.84
SE ±2.84
Mean decrease Mean difference
p = 0.623
8.48±5. 15
0.266 ± 1.07
no significance
p = 0.106
p = 0.806
no significance no significance

.
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4.4. Analysis of H ead Injury & M idazolam/Non-midazolam
4.4.1. Statistical a nalysis of head inj ury vs. systolic blood pressure
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Figure 19. Means ofSystolic Blood Pressure for head injuries
Table 20. Systolic Blood Pressure summary of means and ±SE for head injuries
H ead Inj ury vs.
Systolic Blood
Pressure (SBP)

M ILDTBI
n=56

MODERATE/
SEVERE
TB I
n=40

a) Initial SBP b) Diffe rence
Reading
between
+M &-M
Initia l & Final
SBP read ing
+M
+M =125.2
I = 125.2
SE ±5. 14
SE± 5. 14
-M= 13 1
F= 118.9
SE ±4.86
SE ±4.9 1
Mean
Mean decrease
difference
6.2 1 ±3.45
5.98 ±7.73
p = 0.089
no significance
p = 0.443
no significance
+M=121.4
I = 121.4
SE ±4.55
SE± 4.54
-M = 130
F = 11 6.4
SE±10.7
SE ±4.9
Mean
Mean decrease
d ifference
5 ±3.37
8.57 ±9.96
p = 0. 148
no signi ficance
p = 0.395
no significance

c) Differe nce d) Final SBP e) S~ati stical
between
Reading
Difference
between b) &
Initial & Final
+M&-M
SBP reading
c)
-M
]= 131.1
+M = 1 18.9
SE ± 4.86
SE ±4.9 1
-M = 128.5
F = 128.5
SE±4.39
SE ±4.39
p = 0.099
Mean decrease
Mean
no significance
difference
2.67 ± 1.01
9.5 ±7.07
p = 0.01 2
p = 0.185
xes significant
no significance
+M = 116.4
I = 130
SE± 10.7
SE ±4.91
F= 129.6
-M = 129.6
SE ±9.41
SE±9.41
p = 0.308
no significance
Mean decrease
Mean
0.4 ±0.259
differe nce
13.2 ± 10.1
p = 0.801
no significance
p = 0.1 99
no significance

+M = mtdazolam
-M = no midazolam
I = initial reading
F =final reading
p =significance value
SE± = Standard error mean
Mild TBI = mild traumatic brain inj ury
MIS TBI =moderate/severe traumatic brain injury
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4.4.2. Statistical analysis of head inj ury vs. oxygen saturation

Head Injury v s. O xygen Saturation (Pa02)
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Figure 20. Means of Oxygen Saturation for head injuries
Table 2 1. Oxygen Saturation summary of means and ±SE for head injuries
e) Statistical
Head Inju ry vs. a) Initial Pa02 b) Difference c) Difference d) Final Pa02
Difference
Reading
O xygen
Reading
between
between
between b) & c)
+M & -M
Saturation (Pa02)
+M &-M
Initial & Final Initial & Final
Pa02 read ing Pa02 reading
-M
+M
+M =95.8
I = 96.5
+M =98.3
I = 97.8
SE±0.773
SE ±0.394
SE ± 0.394
SE ± 0. .469
-M =96.5
F = 98.4
-M =98.7
F = 98.7
SE±0.773
SE±O.l76
SE±O. I76
p = 0.432
MlLD TBI
SE ±0.469
n=56
Mean difference Mean increase Mean increase Mean difference no sign ificance
1.25 ±0.433 0.579 ±0.863 2. 19 ±0.447 0.36 1 ±0.602
p = 0.047
p = 0.511
p = 0.000
p = 0.551
~es significance not significant ~es significant no significance
+M =96.4
+M =93.7
I = 93.8
I = 94.2
SE±0.979
SE ± 0.978
SE ± 1.36
SE ±0.7 14
-M =94.2
-M =98.6
MODERATE/
F = 96.4
F = 98.6
SE ±0.40
SEVERE
SE ± 1.36
SE ±0.7 13
SE ±0.400
p = 0.012
TB I
Mean difference Mean increase Mean increase Mean difference ~es significa nt
n=40
2. 17 ± 1.28
2.66 ±0.50 1
4.4 ± 1.1 5
1.25 ±0.433
p = 0.818
p = 0.000
p = 0.004
p = 0.095
no significance ves significant lves sifmificant no significance
+ M = mtdazolam
-M = no midazolam
I = initial reading
F = fillal read ing
p = significance value
SE± = Standard error mean
Mild TBI = mild traumatic brai n injury
MIS TBI = moderate/severe traumatic brain injury
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4.4.3. Statistical analysis of head injury vs. respiration rate

Head Injury vs. Respiration Rate (RR)
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Figure 21. Means ofRespiration Rate for head injuries
Table 22. Respiration Rate summary of means and ±SE for head injmies
Head Injury vs.
Respiration Rate
(RR)

MILDTBI
n=56

MODE RATE/
SEVERE
TBl
n=40

a) Initial R.R
Reading
+M &-M

b) Difference
between
Initial & Final
RR reading
+M
I = 22.6
SE ± 1.31
F = 20.9
SE ± l.39
Mean decrease
1.63 ±0.922
p = 0.094
no significance

+M =22.6
SE±l.3 1
-M =19.6
SE±0.570
Mean
difference
3.01 ±1.43
p = 0.046
yes significant
I = 24.6
+M =24.6
SE±I.39
SE ± 1.39
-M =18.8
F = 21.5
SE±0.742
SE ± 1.68
Mean
Mean decrease
difference
3. 1 ± 1.41
5.8 ±1.58
p = 0.035
yes s ignifica nt
p = 0.001
yes significa nt

+M = mtdazolam
-M =no midazolam
I = initial reading
F = final reading
p = significance value
SE± = Standard error mean
Mild TBI = mild tra umatic brain injury
M/S TBI = moderate/severe traumatic brain injury
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e) Statistical
c) Difference
d) Final RR
· Reading
Difference
between
between b) & c)
Initial & Final
+ M& -M
RR read ing
-M
I = 19.5
+M =20.9
SE ± 1.39
SE ± 0.570
-M = 19
F= 19
SE±0.506
SE ±0.505
p = 0.412
Mean decrease Mean difference no significance
0.486 ±0.211
1.86 ± 1.48
p b 0.221
p = 0.027
yes s ignificant no significance
I = 18.8
+M =21.5
SE± 0.742
SE ± 1.68
F = 18.6
-M = 18.6
SE±0.79 1
SE ± 0.792
p = 0.611
Mean decrease Mean difference no significa nce
0.20 ±0.20
2.93 ±2.97
p = 0.343
p = 0.330
no significance no significance

4.4.4. Statistical analysis of head injury vs. pulse rate

Head Injury vs. Pulse Rate (PR)
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Figure 22. Means ofPulse Rate for head injuries

Table 23 Pu1se Ra te sununary o f means an d ±SE £or 1ead"mJunes
Head Injury vs.
P ulse Rate (PR)

MILDTBI
n=56

MODERATE/
SEVERE
TBI
n=40

a) Initial PR
Read ing
+M & -M
+M =94.7
SE ±4.55
-M =87.7
SE±2.14
Mean
difference
6.98 ±5 .02
p = 0.1 77
no significance
+M = 100.3
SE ±3.44
-M =89.5
SE±7.22
Mean
difference
10.8 ±7.25
p = 0.144
no significance

b) Difference c) Difference
between
between
Initial & Final Initial & Final
PR reading
PR reading
-M
+M

d) Final PR
Reading
+M&-M

e) Statistical
Diffe rence
between b) &
c)

+M =92.6
SE±5.12
-M =8).7
SE±2.07
Mean
difference
p = 0.978
6.92 ±5.52 no significance
p = 0.222
no significance
+M =98.8
I = 89.5
I = 100.3
SE ±3.94
SE± 3.44
SE± 7.22
-M =91.4
F = 98.6
F = 9 1.4
SE±6.84
SE ±6.84
SE ±3.94
Mean
Mean decrease Mean decrease
difference
p = 0.684
1.46 ±0.546
1.9 ± 1.55
7.46 ±7.88 no significance
p = 0.589
p = 0.252
p = 0.349
no significance no significance
no significance
I = 87.7
I = 94.7
SE± 2. 14
SE ± 4.54
F = 85.7
F = 92.7
SE±2.07
SE ±5.1 2
Mean decrease Mean decrease
1.94 ±0.909
2.0 ± 1.5
p = 0.039
p = 0.200
no significance yes significant

+M = mtdazolam
-M = no midazolam
I = initial reading
F = final reading
p = significance value
SE± = Standard etTor mean
Mild TBI = mild traumatic brain injury
MIS TBI = moderate/severe traumatic brain injury
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4.5. Mild TBI Results
Mild TBI vs SBP
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Figure 23. Means ofSystolic Blood Pressure for Mild TBI
T abl e 24 Syst 0 1'IC Bl 00 d P ressure summary o f means an d ±SE fior M'ld
1 TBI

Mild
TBI
vs.
SBP

Initial vs.
Final
SBP
Midazolam
(n= 19)
1 = 125.2
SE ±5. 14
F = ll 8.9
SE ±4.91
p = 0.044
yes significant

Initial vs. Final
SBP
no midazolam
(n= 37)

Initial SB P
reading
+M&-M

Final SBP
reading
+M&-M

Statistical difference
between the
differences
for+M&-M

1= 131.1
SE ±4.86
F = 128.5
SE ±4.39
p = 0.006
yes significant

I = 129. 1
SE ±3.64
p = 0.20 1
no significance

F = 125.2
SE ±~.38
p = 0.078
no significance

Mean difference
3.87 ± 1.35
p = 0.168
no significance

Mild TBI vs Oxygen Saturation
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Figure 24. Means ofOxygen Saturation for Mild TBI
Table 25. Oxygen Saturation summary of means and ±SE for Mild TBI

Mild
TBI
vs.
Pa02

Initial vs.
Final
Pa02
midazo lam
(n= 19)
I =97.8
SE ±0.394
F =98.4
SE ±0.773
p = 0.255
no
significance

Initial vs. Final
Pa02
no midazolam
(n= 37)

Initial Pa02
reading
+M&-M

Final Pa02
reading
+M& -M

Statistical difference
between the
differences
for +M& -M

I =96.5
SE ±0.469
F =98.7
SE ±O.l76
p = 0.000
yes significant

I =96.9
SE ±0.345
p = 0.023
yes signjficant

F =98.6
SE±0.283
p = 0.327
no signi ficance

Mean difference
1.64 ±0.423
p = 0.054
no significance
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Mild TBl vs Respiration Rate
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Figure 25. Means ofRespiration Rate for Mild TBI
Table 26. Respiration Rate summary of means and ±SE for Mild TBI

Mild
TBI
vs.

RR

Initial vs.
Final
RR
M idazolam
(n= 19)
I =22.6
SE ±1.3 1
F =20.9
SE ± 1.39
p = 0.047
yes significant

Initial vs. Final

RR
no midazolam
(n= 37)
I = 19.6
SE ±0.570
F = l9
SE±0.505
p = 0.013
yes significant

Initial RR
reading
+ M& -M

Final RR
reading
+M& -M

Statistical difference
between the
differences
for +M& -M

l =20.6
SE±0.608
p = 0.023
yes significant

F = 19.7
SE ±0.583
p = 0.110
no significance

Mean difference
0.875 ±0.344
p = 0.119
no significance

Mild TBI vs Pusle Rate
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Figure 26. Means of Pulse Rate for Mild TBI

Table 27 P use
1 R at e summary o f means and ± SE f,or M"1ld TBI

Mild
TBI
vs.
PR

In itial vs.
Final
PR
midazolam
(n= 19)
I =94.7
SE ±4.55
F =92.7
SE ±5. 12
p = 0.100
no
significance

Initial vs. Final
PR
no midazolam
(n= 37)

Initial PR
reading
+ M& -M

Final PR
reading
+M&-M

Statistical di fference
between the
differences
for +M& -M

I =87.7
SE±2.l4
F =85.7
SE ±2.07
p = 0.013
yes significant

I =20.6
SE±0.608
p = 0.088
no significance

F = l9.7
SE±0.583
p = 0.111
no significance

Mean difference
1.96 ±0.780
p = 0.488
no significance
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4.6. Moderate TBI Results
Moderate TBI vs Systolic Blood Pressure
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Figure 27. Means of Systolic Blood Pressure for Moderate TBI

Table 28 S,ys t o1·1c Bl 00d Pressure summary of means and ±SE £or M0 d TBI

Moderate
TB I
vs.
SBP

Initial vs.
Final
SBP
midazolam
(n= 16)
I = 127.4
SE±6.69
F = 122.2
SE ±8.05
p = 0.1 83
no
significa nce

Initial vs. Final
SB P
no m.idazolam
(n= 9)

Initia l SBP
reading
+M&-M

Final SBP
readi ng
+M &-M

Statistical difference
between the
differe nces
for+M & -M

I = 131.1
SE ± I 1.8
F = 130.8
SE±10.4
p = 0.450
no significance

I = 128.7
SE ±5.92
p = 0.394
no significance

F =125.3
SE±6.29
p = 0.258
no significance

Mean difference
3.4 ±3 .6
p = 0.202
no significa nce
0
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Figure 28. Means of Oxygen Saturation for Moderate TBI
T a ble 29 0 xygen saturat10n summary o f means and ±SE £or Mo derate TBI

Moderate
TBI
vs.
Pa0 2

Initial vs.
Final
Pa02
midazo lam
(n= 16)
I =92.8
SE±l.46
F =96.4
SE ±1.03
p = 0.000
yes significant

Initial vs. Final
Pa0 2
no midazolam
(n= 9)

Initial Pa02
reading
+M&-M

Final Pa02
reading
+M& -M

Statistical differe nce
between the
differences
for +M &-M

I =94.1
SE ±1.5 1
F =98.5
SE ±0.444
p = 0.004
yes significant

I =93.3
SE ± 1.07
p = 0.272
no significance

F =97.2
SE ±0.702
p = 0.037
yes significant

Mean difference
3.92 ±0.658
p = 0.296
no significance
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Moderate TBI vs Respiration Rate

30,--------=~-----------=-=-25

·~ 20
iii 15
c.
~ 10
5

0~~~==~~~~~~~
Initial ReadiJJ&
Final ReaditJ&

Figure 29. Means ofRespiration Rate for Moderate TBI
T a bl e 30 R esp1rat10n Rate swnmary of means and ± SE flor M o derat e TBI
Initial vs.
Final
RR

midazolam
(n= 16)
Moderate

TBJ
vs.
RR

I =24.9
SE ±1.7
F =21.2
SE ± 1.43
p = 0.028
yes significant

Initial vs. Final
RR
no midazolam
(n= 9)

Initial RR
reading
+M& -M

Final RR
reading
+M& -M

Statistical difference
between the
differences
for+M &-M

I =19.1
SE ± 1.7
F = 18.8
SE ± 1.43
p =0.173
no significance

I =22.8
SE±l.24
p = 0.003
yes significant

F =20.3
SE±0.978
p = 0.089
no significance

Mean difference
2.48 ± 1.19
p = 0.035
yes significant

Moderate TBI vs Pulse Rate
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Figure 30. Means ofPulse Rate for Moderate TBI
Table 31. Pulse Rate swnmary of means and ±SE for Moderate TBI
Initial vs.
Final

PR
Moderate
TBI
vs.
PR

Midazolam
(n= 16)
I =99.2
SE ±4.97
F =95 .7
SE ±6.31
p = 0.219
no
sign ificance

Initial vs. Final
PR
no midazolam
(n= 9)

Initial PR
reading
+M&-M

Final PR
reading
+M& -M

Statistical difference
between tbe
differences
for +M&-M

I =89.6
SE±8.07
F =91.7
SE ±7.63
p=0.127
no significance

l =95.8
SE ±4.3 1
p = 0.165
no significance

F =94.3
SE±4.80
p = 0.346
no significance

Mean difference
1.48 ±2.88
p = 0.124
no significance
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4. 7. Severe TBI Results
Severe TBI vs Systolic Blood Pressure
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Figure 31. Means ofSystolic Blood Pressure for Severe TBI
Table 32 S;ysto r1c Bl00 d Pressure summary of means and ±SE £or SevereTBI
M idazolam (n= l4)
No midazolam (n= l )

Initial
SBP

Final
SBP

Severe TB I
vs.
SBP

mean = 11 5
SE = ± 5.36

mean = 110
SE =± 4.53

Statistical difference
between Initial vs. Final
SBP
p = 0.098
no significance

Severe TBI vs Oxygen Saturation
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Figure 32. Means of Oxygen Saturation for Severe TBI
Table 33 0 xygen saturatwn summary o f means an d ± SE£or Severe TBI
Midazolam (n=14)
No midazolam(n= l)

Initial
Pa02

Final
Pa02

Severe TBI

mean = 94.8
SE =± 1.16

mean = 96.6
SE =± 0.960

VS.

Pa02
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Statistical difference
between In itial vs. Final
Pa02
p = 0.002
yes s ignificant

Severe TBI vs Respiration Rate
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Figure 33. Means ofRespiration Rate for Severe TBI
Tabl e 34 Respuaf wn Ra t e summary o f means an d ±SE flor Severe TBI
Midazolam (n=l4)
No midazo lam (n=l)

Initial
RR

Final
RR

Statistical difference
between Initial vs. Final

Severe TBI
vs.

mean= 23.7
SE =± 2.25

mean = 21.5
SE=±3.08

p = 0.156
no significance

RR

RR

Severe TBI vs Pulse Rate
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Figure 34. Means ofPulse Rate for Severe TBI
Table 35. Pulse Rate summary of means and ±SE for Severe TBI
Midazolam (n= 14)
No midazolam (n= l)

Initial

Final

RR

RR

Statistical difference
between Initial vs. Final

Severe TBI

mean = 100.6
SE = ± 4.62

mean = 101
SE =± 4.25

p = 0.385
no significance

RR
VS.

RR
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5. J)iscussiun
Millazohtrn/Non midawlam analysis
The analysis of the systolic blood pressure (SBP) in relation to midazolam and non·
midazolam cohorts shmnxl a statistical signilicancc bct\'iccn initial and final readings
for cnch cohort (sec table 9). The lower initial SBP readings for the midazoiam cohort
may be a consequence nf the mulliph: injuries sustained by the patients. Such i11jurit:s to
the hl:ad imply greater blood loss. therefore rcsulling in lo\',:cr initial SBP readings s5•
The mean decrease for the midazolam cohort was greater than 5 mmllg which was not
considered clinically significant as patients were not in danger of reaching a
hypotensive state

72

.

There was also a significant diiTcrcncc between the final readings

comparing both midazolarn and non·midazolam cohorts. The tina[ reading for the
midazolam was not as high as the non·midaznlam cohort (sec table 9). llowevcr the
mean final reading was

consid~.:red

safe and was not imlicativc of hypotension.

A statistical significance was also noted bet\vecn the initial and linn\ readings for
oxygen saturation in the midazolam and non·midazolam cohorts (sec table 10). It is
important to note that all patients in this study received oxygen supplementation during
treatment. This explains the increase in final oxygen saturation readings for both the
midazolam and nmHllidazolam cohorts. There is a stutistical significance bc:t\vccn the
final Pa02 rcadmg between midazolam and non-midazolam cohorts. Midazolam·s !ina!
PaO~

readings increased to 97% compared to a 99%

PaO~

increase for the non·

midazolam colwrt. Again this may he due to the severity of injuries sustained by the
midazolam study ptlpulation.

Tbl! analysis of respiration and pulse rate in relation to midazolam and nmHnidazolam
cohorts revealed a signilicant di!Tcrcncc hcl\vccn initial respiration and pulse rate
reading for the

mida;.~olam

cohort (tables 11 & 12). Patients treated with midazolam

expressed higher initial respiration and pulse rate readings compared to no!Hllidazolam
patients. This may be Juc tu the fact that patients treated with midazolam displayed
um:ontro\lablc or aggressive

behaviours which directly correlate to

increased

physiological breathing and ht:art rate patterns. Although there \Vas a noted statistical
di!Tert:nce between initial respiration and pulse rate readings for the midazolam cohort
this was of no clinical signilicance.
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Gender category
In relation to the companson of initial and linal readings, midazolam and non·
midazolum groups for males, it \vas interesting to note that there was a significant drop
in SBP (sec table 13. figure 10). This translates to a signilicant drop in oxygen
saturation when comparing these same groups; IHl\\evcr this is not or diniL'ai
importance ami probably relates to the naturl.! of the injuries of thi.! group. It must bL•
borne in mind th<lt the patients selected

to

receive midazolam were not randomly

selected. but were allocated the drug on the basis of their antisocial or unL'ontrolbhlc
behaviour. This ClHild

ac~.:ount

for the dilli:renccs noted between initial n:adings of both

midazolam and nmHniJazolam group in respect of puls-e and rL'spimtion rate.
Dirt~renccs

between the initial readings of these groups in n:spcct ofoxygL'll satumtion

and blood pressun: were also noted. but Wl.!rc nPt or stutisti~:al signi licancc.

The analysis of oxygen saturation on the basis of gender 1\.'\'ca\cd no signiticant
dift~tcnccs

between initial and tina\ rcadin~s. in those patil..'nts given midazolam rdati,·e

to those patients who did not receive midnml.1m for citlwr thl.! males or fcmaks. Yet the
males displayed a signiticant drop in !ina\ reading under the irtluencc of mida;.olam
(sec table 14). Discounting physiological dirt'erencl.!s. this rt.d1ccts tht: seriousness of the
injuries of the male cohort. especially in rdntion to hc.:~d i11iurics. whkh mainly arosl.! as
a conscqm::ncc of motor n:hich.: accidents. The m~~iority of maks in this study m.:rc
aged between 25 to 35 years and were involved in motor vehicle accidents. wbill.! the
majority of Ji:maks were agl..'d 66 years and o\dl..'r and sustained head injuries due to
lUlls and direct trauma to L,~·~ head. This natural bias in the data could not he overcome
due to the limitations nf complete patient care records.

Age category
The age vs. Systolic Blood Pressure category did not present statistical signillcanet: for
the Jess than 35 year olds. In this category. patients treated with mitlazolam recorded
14.3 mm Hg less than those not treutcd with midazolam. The under thirty lives showed
a 6.2 mm Jig mean dccn.:asc for the mida1-olam patients compared to a 2.8 mm Jig in
the non·midazolam group (sec tabll.! 17).

A statistical signiticancc was noted in all hut three variables in relation to age vs.
oxygen saturation. Patients 35 years and older recorded similar 111\!all oxygen saturation
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midazolam cohnrt displayed a higher initial n:spiration rate than

th~.:

mild head injuries

no-midazulam C\lhnrt the greater decn:asc in breathing rate after administration of
mida...:{ll.un shm\cJ this to he of nn clinical signilicancc.

l'<.~ticnts tr~:atl'd

''ith midawlum

displa:-~.:J

higher initial anJ final pulse rate reading

than the nun-nmla;n\am cohnrt. This cotllJ he due th..:

l~1..:t

that tb1.• patients tn:ateJ \\'ith

midan1lam an.: a sdcl'l gru11p displaying uncontrtl\\ablc or aggrcssi\'e hehaviours. When
C\llllparing pulse rak bd\\een mida/llla!ll and nun-midamlam cohorts. a larger drop in
pulse rate \\as nuted \\ ith the non-mida/_o\am cohort.

.\lnLkr;l!~.·

1kud injurv

A statisti..:all)

signiticmlt mereo1se

Ill

11Xygen saturmion \\as recorded for both

midMolam and Twn-mid<JJ.nlam patient:-;. Statistical signiticanee was abo noted fm the
mean tinai

u:-..~go.:n

:-.atur•ttiun n:adin);

rceei\t:d

'fk"u during la:dd

n\~gen

table ]0) hci\\O.:l'll the mida;:nlam and nnn-

r~.·aeh

9K"o. It is important th;u o.':-gen s.:tturatiun

triHIIl1<1.

1\tl\\f.!\l'f. patient:> \rL':lt..:d Juring this study all

midazulam p:1tienh: it duo.:s Tl\lt
re;H.Iin~s r~.·;Kh

iS~.:e

·.uppknH:nt:ttinn and

P\~gen

saturatiun I'L'adings \\o.:re carefully

maintained and 11\Pilil\lfi.!d. :\ 1JX" o tl\) gen saturaliPn reading docs THlt indio.:ute

h~

pu:da

ami is ofntllktrimental~.·fket to paticnts 1 ~>. (>IlL' ofthL' prnhlems in interprl'till); the data
i. . the

uncertain!~

sy.~tcms.

nf \lhat phamT<tL'L·uticuls tor Ptha drugs) the

p<~tienls

h;L\1.' in their
ag~.:nb

from

The larger drup in breathing rate lilT the !llida/.\llam Ctlllllrl eomparcd tn tlnly a I. 7

re~ps

per minuto.: drup in the non-midal\ll:un su):!gt.:sts midah1lmn patio.:nt:-. Jisplayl'd

l~tster

•mJ \l]ll.'th..:r the :H.illliJli..,tratillll 11f mid:lllll:illl

thL' tran . . ptlrt pn1tt:i1b

breathing

jMlkm~

111

I\

ill Ji.-;place these

the bhl{llbtre:llll. pn1ducing multil';.u,:torial erti:ets.

than the patient:-. lllltlrL'<LtL'd \\ith mid<J;:p\;un.

:\g<~in

this ma:- he du1.'

111 e;tch p;t\IClll trL·all'd 11ith mida/11lam di:-.pb,1ing :tggrL'ssile ur lllll.:tltlJll.'ratile
hdla\Hlllr:-. thcrdill'l' tho.:se p<itll'llls'

ph~ ... iolugiea\

respon.~L':--

\\l'ft: increasL·d. Abtl.

although till' mc,ll\ initi.d read in):.' \Ia:-- higher in midil!tllan\ patients than nun-mida;nlam
patiL·nts \see tahk _\I). •dl patiL'llb
hrt.:<tthing

pal1L'Jil~.

tr~.·ated 11

ith lllidalllkilll did 1111t Ji:-,p\a~ irregul;1r

I be 1\ll'rall drop in re:-.piratioa r;tll' did no\ i'L'aL·h

le1L'I~ liu· indi1 idu;ds

·m ·II

clini~.·;Ll

dwll,!l'r

No statisti(.;a\ significam:c was found with systolic blood pn:ssun:: or pulse rate bl!twccn

mid.:1zolam treated p<.tticnts and untrcaLt.:d patients. Jlnwcvcr the midazolam cohort
displayed a

\nW~:r

s,;.stnlic blnoJ prcssun.: (sec tahh:

tina\ n:aJings ''hen compmeJ tu

<1

cohort.

p:1tients

This is

unusual

<ts

2~)

for hoth the initial TCllding and

much higher systolic rcmling for the non-miJazo\am
n.:cci,·ing midazolam display

aggrcsstvc

charm:\l.:ristics that could inllm.•ncc incn.'<t<>cd symptoms of hypuh:nsiun. 1\owcn:r, this
cnu\J he i..!XplaincJ as patio.:nts treated with midazolmn suswincJ a slightly higher CJCS
score. which suggl..'sts the more severe thL' h~.-·ad injury the greater th~.:: hloml loss

.
'h y pal .tents "' .
cxpcr!l.!llt:l'u

Scn:n: I kaJ !njurit.'s
lhl' mt.'an drop in

s~ :-.tnli~

hloml prt.'S'>t:rt: for the st:vt:rcly ht:ad injurt:d patients is 5mm

llg. Thl..' initial SBP reaJillg
within

th~

(s~e

table ]3) was not consiJen:d high and in raet it is

nnrmal ht.'ahhy range. The drop in SBP is

th~.:n:forc

not clinically signilieant

to patil'nts. as tlwy "~re nnt hypott:nsiw x.'.

A

statisti~..:al

signific:mce in thl: inncasc or (lXygen :-.aturation was

lltlt~J.

I [ll\\e\'l'T tht:

increase is not clinically signiflt:illll c\·en tlwugh the tina! oxygen saturati\m docs not
re.:1ch 'J7"-,. It is important to puint out tlwt the patients in the modt.'ratc ht:ad injury
category h.:1W a 1\lO...:illl nf 'J7"·;)

ox~gL'I1

patients. Tlw litl't tlwtthL· se\ercly
patil'nts had :-.imil.:tr
SPSS study. 11

during

h~:ud it~iurL·d

O\~):!L'!l :-.<~turatiun

i~ al~o

tran~p(lr\atiun

saturation. thl'

to

:-.upp,lrlillt'
hu~pital

l'\

~am..:

as the

s~:wrd~

bead injured

patil'nts <tnd the nwderate ht.'aJ injun.:J

lc\cls \aliJates t:l.llllhining tlwso...: groups in thl.!

idL'llCL'

th<~t

thL' k·\ el uf \lX)gcn administration

IS itppropri;t!L' lilT o.:;tdl ur tlll' . . (: patio...:nl

shuuld h..: hunK in mimi that :m:. pnl!.:ll\ial dh.·cts uf

n.:duL·in~

miJ;l/l.l!<ttll WuiJ hL' l'Ullll\(:r<ll'\l:d h~ thl' aJmini:-.tra\il.lll \lr{l:\~~L'n

~.::atcguri..:s.

It

{1.'\ygo.:n suturation by
'·'I.

1\u ditHcal :-.igniti•:alli.:L' \\as 110k'd \\ith r(:spiration rat..: nr puis(: rate in tilL' Sl'\·crdy

head injun:d C11hnrt. The se\Cr(:ly head injur(:d p<ttiL·nts displayL·J slightly higher

injured paticnts.

)ll\(:I'L'Stingl~

th...:~

di~p\;•)Cd

hml'r

breathing rak redding-. than thL' nlo,krak h..:ad injunL'S.

:-.~stnli~.:
lhi~

blood

pr~ssurc

and

nwy hc due to S\\1.dling

impinging nnth..: canhu\a:-.cular mo.:dul!ar) co...:ntrl.'s in the brain)('.

Comparing

th~

analysis of

th~

mild vs.

mod~ratc/s~vcrc h~ud

injurit:s in the

Exc~.·l

analyses slllm~d no t.listim:t Jifll:r~ncc hi•.'twccn the two cohorts. Both t\wsc cohorts
displayed statistically ~;igni1icant dilkrcnc~s in oxygen saturation n.:mlings and a
statistical signilicancl' found in syswlk blouJ pressure.
patients

r~cciving

mida;u\am relative tn

untrcat~d

r~spiration

patients.

rate or pube rate in

Alsn when comparing

nllld~ratl'

\·s. s1:wrc head injuries oxygen saturation \"aria hies stoud out and Doth cllhorts

disp\ay~d

statistical significance suggesting hypoxic acti\"ity is prcs~nt in tr~atcd

pati~nts.

6. Conclusion
This stlldy has JcmonstrntcJ that mit!azol~un is a sati: ami ert~ctivc sedating agent used
in the treatment nf aggressi\'e anti unctmtrollabk• patients who hiiVC sustilim:J a head

lllJUry. The tlt1sage of mid;unlam used on patients in this study ntrid rnllll 5mg In
25mg. Tht: patients \\ho received 25rng ot' miJawlam displayed similar physiological
effects to those patients \\ho only recei\·ed 5mg of midazolam. Ultimately the
dosage of mida1nla111 used to tre<tl aggressin: heaJ injureJ p<1ticnts Jues not
im:rease in either

hypot~·n:-.inn

\'ari~.·J

eaus~.:

an

or hypoxia.

It is interesting to speculate what woukl happen to oxygen sawration rt:adings if no
ux~ gen

supplcmentatiun

wa~;

administert:d to

patients Juring

mid<u:olam'! \\'hat \\nuld oxygcn saturatinn levels be? It is our

treatment

sp~·eul<ttion

with

that oxygen

saturation lc\els \\lll!]d in fact remain f<tirly low if no oxygen supplcmcntation ''as

giH'B tn patients Juring
mida!ol<llll ,,-,1uld

mid~lzolam

tx· anticir<tted

usc. lhen.:fore hypnxia in patient's udminisiered

7
''I. :-_

lncrcases in respiration raiL' in patients tre.:tted with midawlam appear in the g~nder. age
and hl.!ad injur) gruups. i\'lidawl.:un may lx.· more <11.!\i\'e on the respiratory C!.:"llii\!S of the
brain

sli.!lll

fpuntine) than the cardiovas<.:ul.:tr lllL·dul!ary

Ci.!lltr< ... -lh

Ultimately this study fuund miJat.olarn treatmcm did in!lut.'llL'I.'

d~.·,:rcasc

in SBP. an

incr :asl.! in pulse rail' and hew1 ratc ' ~dong with lnwl.:"r oxygen saturatitlll lcvds.
11

1\il\\e\'l'r. in this study thc \';triahles an; of no clinical signilicanct: ~'~- ·~~

'l.1

and do not

sug).!est h)pnxia t•r hyptl\cnsinn in patients. On the basis ufthis data and the

anal~:-es

carried out. thcrc \\L're no Jemon:-trahlc dell'tcrious dkcts of midazulam nn uxygcn
saturatiilll or hlouJ prL·ssurc in head injured patients. This is supporting evidence that
this is a comparati\cly sali: drug fur usc in the prehospital setting.
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Appendix 2

STJOHN AMBULANCE AUSTRALIA
W.A. AMBULANCE SERVICE INC.

Clinical Practice Guideline 20
September, 2004

HEAD TRAUMA:
Assume cervical injury until proved otherwise refer to CPG 31 (Indications for
Spinal Precautions).

Specific information needed:
History:
•
•
•
•
•
•
•

Mechanism of injury.
Estimate of force involved, potential for concealed injury.
Change in level of consciousness since injury.
Amnesia for events prior to and/or following trauma.
With motorcycle, bicycle and industrial accidents, was a helmet
worn?
How does patient feel? Movement, sensation, numbness, tingling.
Brief relevant past history medical problems, medications.
M

Specific physical findings:
•

Vital Signs (note respiratory pattern and rate).

•

Level of consciousness (GCS). When assessing children less than

14 years of age use AVPU.
•

•

Neurological examination, including pupils and response to
stimuli, and record findings. NOTE differences between sides.
(Skill 103)
External evidence of trauma (abrasions, lacerations, etc.).
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Management:
Danger, Response, Airway, Breathing, Circulation Disability £xposure.

Jaw thrust or oropharyngeal airway as needed.

Noisy breathing is obstructed

breathing.
Be alert for airvJay problems and/or seizure activity. If indicated, consider advanced
airway management.

Oxygen, high concentration or 100% (venti13le if necessary) to maintain oxygen
saturation of at iaast 90%.
lmmobilise cervical spine with collar and sandbags. Patients with suspected
head/neck in~ury may be agitated and may not to!erate application of collars. Do not
force collar~ on under these circumstances.
Scalp bleeding may be stopped by direct local pressure. If the underlying skull is
unstable, pressure should be applied to the periphery of the laceration over intact
bone, using a lar~e pad.
I
If patient has other senou::; lnjuries, these will have priority.

I

If evidence of poor peripheral perfusion, administer i/v fluid to maintain cerebral !I
perfusion and conscious level Try to maintain a systolic blood pressure of at least 90
mmHg. Consider MAST if no other option is available.
]
For longer transport times, if practical manage patient with upper body raised 30° to
decrease cerebral oedema (unless hypotensive). Ensure head neck alignment is
maintained.
If altered mental state, check BSL.
Monitor Vital Signs and level of consciousness at scene and during transport.
STATUS CHANGES ARE IMPORTANT. Record findings.

Specific precautions/notes:
•

The most important information you provide for the hospital is
TIME SEQUENCE OF LEVEL OF CONSCIOUSNESS.

•

Is the patient stable, deteriorating or improving?

•

Assume cervical spine injury in all patients with significant head
trauma.

•

Any patient with even a transitory loss of consciousness should be
assumed to have sustained significant trauma to the brain.

IF PATIENT WITH HEAD TRAUMA IS IN SHOCK, LOOK ELSEWHERE FOR
POSSIBLE CAUSES. SHOCK IS PROBABLY NOT DUE TO HEAD INJURY.
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Additional Notes
Restlessness/aggressiveness can be a s1gn of hypoxia Corobral hypoxia is
tho most frequent cause of death in head injury. /1.
AIRWAY IS
ABSOLUT[LYVIIAL

c;ooD

The llf:<-Hl lflJlHt'd pt~tu~nl wtth ,-i c.omprCHllt~,l~d

;ww<ty .;twl:H
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concentrilttnt; 0. dnr! v(~nt!latnly support 1f ft'IJlmt:d

~){~ flliln<l(Jf:d

tn the

provtrll!l~l ht~Jh
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Appendix 7.

Bnx plot dcmonstrutc.·s normality for Systolic Blood l,rcssurc in mules
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plot demonstrates normality for Oxygen Snturation in males
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Appendix I II.

Box plot demonstrates normality for Oxygen Saturnliun in fenutles
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Box plot dl·monstrulcs normulity ror l{cspirnliun l{ntc in rcm11lcs
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Appendix 15.

Hox plot demonstrates norm:11ity fur Syslulic Blood l,rcssurc in age catc~OI'}' less
tlmn 35 years
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Appendix 16.

Box plot demonstrates normality for Systolic Blood Pressure for age category
greater than 35 years
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Appendix 17.
Box plot demonstrates normality for Oxygen Saturation for age category less than
35 years
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App•ndix 18.
Box plot demonstrates normality for Oxygen Saturation for age category greater
than 35 yc11rs
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Appendix 19.

Box plot demonstrates normality for Respiration Rate for age category less than 35
years
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Appendix 20.
Box plot demonstrates normality for Respiration Rate for age category greater
than 35 years
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Appendix 21.

Box plot demonstrates normality for Pulse Rate for age category less than 35 years
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Appendix 22.
Box plot demonstrates normality for Pulse Rate for age category greater than 35
years
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Appendix 23.
Box plot demonstrates normality for Systolic Blood Pressure in mild TBI cnscs
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Appendix 24.
Box plot demonstrates norno:dity for Systolic Blood l,rcssurc in
TDI cases
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Appendix 25.
Box plot demonstrates normality for Oxygen Saturation in mild TBI cases
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Appendix 26.
Box plot demonstrates normality for Oxygen Saturation in moderate/severe TBI
cases

moderate I severe TBI
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Appendix 27.
Box plot dcmonstrntcs normality for Respiration Rate in mild TBI cases
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Appendix 28.
Box plot demonstrates normality for Respiration Rate in moderate/severe TBl
cases

moderate I severe TBI
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Appendix 29.
Box plot demonstrates normality fur Pulse Rate in mild TBI cases
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Appendix 30.
Box plot demonstrates normality for Pulse Rate in moderate/severe TBI cases

moderate I severe TBI
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